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Circadian Regulation of Temozolomide Sensitivity in Glioblastoma 
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The safety and efficacy of multiple cancer chemotherapeutics can vary as a function of 
when during the day they are delivered. This study aimed to improve the treatment of 
glioblastoma multiforme (GBM), the most common brain cancer, by testing the efficacy of the 
DNA alkylator Temozolomide (TMZ) on GBM in vitro and in vivo as a function of time of day. 
We found cell-intrinsic, daily rhythms in susceptibility of GBM tumor cells (mouse astrocytes 
deficient in NF1 and p53 signaling) to TMZ in vitro. The greatest TMZ-induced DNA damage 
response, activation of apoptosis and growth inhibition, occurred near the peak expression of the 
core clock gene Bmal1 in cultured GBM cells. Deletion of Bmal1 abolished rhythmic circadian 
clock gene expression and circadian rhythms in TMZ-induced activation of apoptosis and growth 
inhibition in GBM tumor cells in vitro. Taken together, these data suggest an important role for 
the core molecular clock in regulating the tumor cell-intrinsic response to TMZ-induced DNA 
damage. These results may be important broadly for how we design TMZ and other DNA 
damaging approaches to GBM treatment.
[1] 
 
 
Chapter 1: Introduction 
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Overview 
 This thesis brings together two fields of study: neuro-oncology and chronobiology. The 
studies performed to complete this thesis harness the power of circadian biology to improve upon 
current treatments of glioblastoma multiforme (GBM). This introduction reviews the research 
that has illuminated the molecular biology underlying brain tumor biology. We propose that 
timing the delivery of chemotherapy to biological rhythms within brain tumor cells, a concept 
known as chronotherapy, will provide a new opportunity to improve clinical outcomes for a 
patient population in desperate need for improvements in current therapies. To help you 
understand how chronotherapy works, this introduction will describe daily rhythms in behavior, 
physiology and cellular processes and how they can impact the response of the tumor and the 
host organism to chemotherapy. 
The History of Gliomas 
While studying a brain tumor at gross and microscopic levels in 1863, Dr. Rudolf 
Virchow described similarities between the morphology of the tumor and healthy glia. He 
created the term “glioma” to describe these glia-like tumor cells [1]. In an effort to improve the 
classifications of gliomas, Dr. Percival Bailey, under the tutelage of Dr. Harvey Cushing, 
examined 414 pathological glioma specimens and corresponding clinical records. Bailey was 
able to divide these tumors into 13 categories. In 1926, Drs. Percival Bailey and Harvey Cushing 
published this new classification system in “A Classification of the Tumors of the Glioma Group 
on a Histogenetic Basis with a Correlated Study of Prognosis.” This book described a grading 
system for gliomas using histological characteristics of the resected tissue as well as clinical 
records, which provided the first demonstration of the prognostic value of microscopic histology 
of brain tumors[2]. This system of categorization formed the basis for all future glioma 
[3] 
 
classification systems, including the currently used classification guidelines of the World Health 
Organization (WHO). The WHO grading system takes into account nuclear atypia, mitotic 
figures, microvascular proliferation and necrosis to categorize gliomas. Astrocytic tumors are 
divided into 4 different grades, with the most malignant tumors in the highest grade (summarized 
in Table 1.1). Within the WHO classification system of grade IV astrocytomas, there are 3 
clinico-pathological variants of gliobastoma with distinct International Classification of Diseases 
for Oncology (ICD-O) codes: classical, gliosarcoma and giant cell glioblastoma. There are other 
patterns of pathology in addition to these variants, including small cell glioblastoma and 
glioblastoma with oligodendroglioma component [3]. Recently recognized GBM variants include 
Fibrillary/epithelial GBM, Small cell astrocytoma , GBM with primitive neuroectodermal tumor 
, GBM with oligodendroglioma component, gemistocystic astrocytoma, granular cell 
astrocytoma  and pediatric high grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG) 
[4]. These emerging GBM subtypes will likely become WHO-recognized variants if the subtype 
has unique molecular features and prognostic value (Table 2,[4]).  
 
 
 
 
 
 
[4] 
 
Table 1.1. WHO Classification of Astrocytic Tumors (adapted from Louis, DN et 
al. 2007[3]) 
WHO Grade I II III IV 
Pilocytic 
astrocytoma 
x    
Subependymal 
giant cell 
astrocytoma 
x    
Diffuse 
astrocytoma 
 x   
Pilomyxoid 
astrocytoma 
 x   
Pleomorphic 
xanthoastrocytoma 
 x   
Anaplastic 
astrocytoma 
  x  
Glioblastoma    x 
Giant Cell 
glioblastoma 
   X 
Gliosarcoma    X 
 
The most aggressive astrocytoma, glioblastoma multiforme (GBM), accounts for 15.6% 
of all primary brain and central nervous system (CNS) tumors and 54.4% of all gliomas [5]. 
Neoplasms are rare in children, but brain and CNS tumors are the most common type of cancer 
among children and adolescents, ages 0 to 19 years, with an annual age-adjusted incidence rate 
of 5.42 per 100,000 in the United States [6]. Pediatric high grade gliomas (HGGs) combine 
GBM, anaplastic astrocytoma and diffuse intrinsic pontine gliomas (DIPGs) and occur with a 
frequency of 0.8 per 100,000 children diagnosed per year[7]. Pediatric GBM accounts for only 
approximately 3% of CNS tumors in children and adolescents, age 0 to 19 years [4, 5]. Long-
term survival of pediatric GBM is greater for infants compared to older children [4, 8, 9]. Unlike 
adult GBM, pediatric HGGs frequently have driver mutations in key epigenetic regulators. 
[5] 
 
Mutations in the gene encoding Histone H3.3 change lysine residues in the histone tail (K27M, 
G34R or G34V). Mutations in histone H3.1 (K27M mutations in HIST1H3B or HIST1H3C) 
occur in 12-31% of pediatric HGGs, but have never been found in adult GBM [7] . These 
mutations alter post-translational modifications of these histone proteins, changing epigenetic 
regulation and causing dramatic changes in gene expression [10]. Brain and CNS tumors occur at 
a higher rate in adults, with an annual age-adjusted incidence rate of 27.86 per 100,000 in the 
United States [6]. Adult GBM can be divided into two clinical subcategories: primary and 
secondary GBM. Primary GBM develops de novo and has a mean age of onset at 62 years. 
Primary GBM accounts for 90-95% of all GBM and is associated with a worse prognosis. 
Secondary GBM arises from grade II or III astrocytomas, accounting for only 5-10% of all GBM 
[11-13]. Secondary GBM has a younger mean age of onset (45 years), far more frequent 
mutations in isocitrate dehydrogenase I (IDH1; 70% of secondary GBM versus <5% of primary 
GBM; [7]) and better prognosis (overall survival of 12-36 months for secondary GBM vs 6-12 
months for primary GBM; [11, 13]). Across the globe, GBM affects more males than females. 
This is true for pediatric and adult GBM [14]. Clinical features of GBM help us predict outcomes 
for future patients, but we need to understand more about the underlying biology of GBM in 
order to create better treatments. 
GBM has recently been divided into subtypes based on genetic alterations. The majority 
of GBM tumors occur de novo, classifying them as primary GBM. Gene expression profiling of 
GBM has led to subclassification based on dominant genetic alterations. Phillips and colleagues 
used DNA microarray to divide 107 high grade gliomas into three molecular subclasses: 
mesenchymal, proliferative and proneural  [15]. Using glioma expression profiles from The 
Cancer Genome Atlas (TCGA) database, Verhaak and colleagues described four molecular 
[6] 
 
subtypes: classical, proneural, neural and mesenchymal [16]. There were great similarities 
among the proneural groups between Phillips and Verhaak. The same was true for mesenchymal 
subtypes created by each research group [11]. The proliferative subtype defined by Phillips and 
colleagues was further subdivided into classical and neural by Verhaak and colleagues. Some 
experts suggest these subtypes are simply mesenchymal or proneural, with higher levels of 
genetic alterations associated with cell cycling and proliferation [17].  When comparing the 
clinical features of proneural to mesenchymal in both studies, the PN subtype is more commonly 
associated with secondary GBM and better clinical outcomes [11]. MES subtype is associated 
with older patients, a worse prognosis and is more frequently seen in recurrent GBMs [11].  
The subtyping created by Verhaak et al., is more frequently cited by brain tumor 
biologists and neuro-oncologists. According to Verhaak’s study, classical was associated with 
amplification of chromosome 7, loss of chromosome 10 and frequent EGFR amplification and 
CDKN2A loss. Many tumors belonging to the proneural subtype had high expression of 
PDGFRA and frequent point mutations in IDH1. Neural was classified by expression of neuronal 
markers, like NEFL, GABRA1, SYT1 and SLC12A5. The most common genetic alterations in 
the mesenchymal subtype were mutation or loss of neurofibromin 1 (NF1), mutation of PTEN or 
TP53 [15, 16]. The genetic alterations described by the Phillips and Verhaak studies are 
summarized in Table 2. These molecular subclasses allow us to model common genetic 
alterations in our research in order to gain greater understanding of the molecular mechanisms 
driving glioma tumorigenesis and response to therapies. The murine glioblastoma model used in 
our studies mimics mesenchymal GBM by simulating mutations of NF1 and TP53, two of the 
most common genetic alterations of that subtype.  
[7] 
 
Table 1.2. Summary of molecular subtyping of gliomas, according to Phillips and Verhaak 
studies (modified from Morokoff et al, 2015 [11]).  
Glioma 
Type 
Glioma 
subtypes by 
Phillips et al. 
2006 
Glioma 
subtypes by 
Verhaak et 
al. 2010 
Clinical 
Features 
Genes or 
chromosomes 
amplified or 
overexpressed 
Genes or 
chromosomes 
deleted, mutated 
or 
downregulated 
Grade III 
glioma 
Proneural 
(31%) 
Proneural 
(20%) 
Better 
prognosis,             
younger age 
PDGFRA 
amplification,          
MYC 
amplification,            
OLIG2, 
PI3K/mTOR,                  
Hedgehog, Wnt, 
Notch,                                         
CDK4 
amplification,             
SOX2 
amplification,              
DCX, DLL3, 
ASCL1,                 
TCF4, CXCR4,                             
ALT-Positive 
IDH1 mutations 
(common),             
TP53 mutations,                      
ATRX, 1p/19q loss, 
CIC, TERT,                               
FUBP1, COX2, 
IGFBP2,                
Annexin1, TAZ, 
PIK3CAP/PIK3R1, 
4EBP1  
Secondary 
GBM 
Primary 
GBM 
Proliferative 
(20%) 
Classical 
(30%) 
Methylated 
MGMT 
status only 
confers 
better 
survival in 
classical 
group 
Chr7, 19, 20 
amplification, 
EGFR 
amplification,               
NES, Sonic 
Hedgehog 
EGFRvIII (activating 
mutation),           
Chr10 loss,         
CDKN2A deletion, 
FAT1 inactivation, 
MGMT methylation 
(silencing) 
Neural (17%) No data 
NEFL, GABRA1, 
SYT1, SLC12A5 
(neuronal 
markers) 
No data 
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Mesenchymal 
(49%) 
Mesenchymal 
(33%) 
Worse 
prognosis, 
older age, 
recurrent 
tumors, 
angiogenic, 
necrotic, 
inflammatory 
infiltrates, 
MRI 
enhancing 
EGFR, PI3K/Akt, 
CHI3L1, YKL40, 
vimentin, MET, 
CD44, MERTK, 
TGFbeta/BMP 
TNF Family,    NF-
kappaB, CXCR4, 
CD31, VEGFR-2, 
S6-kinase, Snail 
NF1 loss/mutation , 
TP53 mutations, 
PTEN, TSC2, tuberin 
As clinical treatments for gliomas have changed over time, prognosis has gradually 
improved. As early as 1884, neurosurgeons were removing brain tumors with very small impact 
on patient survival. Even Dr. Walter Dandy’s radical hemispherectomies were not sufficient to 
eliminate GBM from the brain. The diffuse spread of GBM through the brain made it difficult to 
remove the tumor in its entirety. Other methods were required to eliminate the tumor cells that 
could not be removed surgically. In the 1950s, physicians started to use radiation therapy to treat 
high grade gliomas. In 1958, Frankel and German published a study demonstrating a significant 
increase in survival for high-grade glioma (HGG) patients who received radiation therapy after 
surgical resection [18]. Some of the chemotherapies originally developed for the treatment of 
leukemias and other solid tumors had good penetration of the blood brain barrier; these therapies 
were tested in high grade glioma patients [19]. Nitrosurea, a DNA alkylator, provided a modest 
improvement in survival to patients with grade III or IV astrocytomas, but the addition of other 
chemotherapies did not improve patient survival [20]. Clinicians and scientists spent decades 
trying to find new ways to improve upon the current treatments. Many chemotherapeutics were 
used, but only one blood brain barrier- permeable DNA alkylator was able to extend survival 
[9] 
 
beyond surgical resection and radiation therapy. In 2005, Stupp and colleagues ushered in a new 
age of glioblastoma treatment: the Temozolomide era. 
The Temozolomide Era of GBM Therapy 
In a landmark study published in the New England Journal of Medicine, Stupp and 
colleagues improved GBM outcomes by administering radiation therapy and temozolomide 
(TMZ) chemotherapy concomitantly, followed by a course of adjuvant TMZ therapy. The addition 
of the DNA alkylator TMZ extended median survival by 2.5 months compared to surgical resection 
and radiation therapy alone. Despite this minor lengthening of median survival, the addition of 
concomitant and adjuvant TMZ led to a more than two-fold increase in 2-year overall survival 
(10% to 27%; [21]). After decades of clinical trials providing no significant benefit to GBM 
patients, the seemingly modest lengthening of survival provided by temozolomide is a major 
advancement.  
At physiologic pH, TMZ spontaneously converts to its active metabolite, monomethyl 
triazenoimidazole carboxamide (MTIC). MTIC methylates DNA bases at a variety of locations, 
including positions N7 and O6 on guanine. The O6-methyl-guanine modification is the most toxic 
lesion created by MTIC. Errors in repair by the mismatch repair system lead to double strand 
breaks, DNA damage response and apoptosis.  
The most completely described mechanisms of resistance to TMZ are modifications in 
DNA repair. Loss of DNA mismatch repair prevents the formation of DNA double strand breaks, 
rendering cells resistant to TMZ therapy [22]. The DNA repair enzyme O6-methylguanine-DNA 
methyltransferase (MGMT) is a suicide enzyme which undergoes degradation after removing a 
methyl group from DNA. Overexpression of MGMT leads to resistance through a higher rate of 
[10] 
 
removal of the DNA methylation caused by MTIC. If the MGMT enzymes outnumber the O6-
methylguanines, the tumor cell will avoid activation of the DNA damage response and subsequent 
cell death. Silencing of MGMT expression by methylation of the MGMT promoter is seen in some 
GBM patients. These patients derive greater benefit from radiation and TMZ concomitant therapy 
than patients with no methylation of the MGMT promoter [23]. Since the publication of that study, 
MGMT promoter methylation status has been used as a biomarker to guide treatment of GBM 
[24].The human U87MG glioblastoma cell line used in this thesis has hypermethylation of the 
MGMT promoter, silencing expression of this enzyme and rendering these cells more susceptible 
to TMZ-induced cell death [25]. The MGMT promoter methylation status of our mouse model of 
mesenchymal GBM (Mes-GBM astrocytes) is currently unknown. Thus, two DNA repair 
mechanisms, MGMT and MMR activity, contribute to TMZ resistance in glioma cells.  
Despite initial response to standard therapy of surgical resection, radiotherapy with TMZ 
and 6 cycles of adjuvant TMZ, GBM prognosis remains poor with a median survival of 14.6 
months [26]. Development of new therapies is important, but equally important is the optimization 
of currently available therapies for patients who are fighting to survive brain tumors now. 
Chronotherapy: Application to cancer patients 
Chronotherapy is the improvement of treatment outcomes by minimizing treatment toxicity 
and/or maximizing efficacy through delivery of a medication according to biological rhythms 
within a patient [27]. This concept has been applied to a variety of medications, including 
chemotherapeutics.  
The most successful application of chronotherapy was to the treatment of children with 
acute lymphoblastic leukemia (ALL). Between 1976 and 1984, Rivard and colleagues reviewed 
[11] 
 
the charts of 118 pediatric ALL patients receiving maintenance chemotherapy of daily 6-
mercaptopurine (6-MP) and weekly methotrexate (MTX) in the morning or evening. Of the 118 
patients, 82 received 6-MP and MTX in the morning, while the remaining 36 received the same 
medications in the evening. Disease-free survival was longer for children receiving 6-MP in the 
evening [28].  Based on the exciting results of this retrospective study, Schmiegelow and 
colleagues designed a prospective trial to examine the progression-free survival of 294 children 
with non-B cell ALL treated with 6-MP and MTX in the morning versus evening, or on a 
miscellaneous schedule. ALL patients treated in the evening had a significantly higher probability 
of event-free survival (0.82 evening versus 0.57 morning, p = 0.0002). This difference resulted in 
a 2.56-fold increase in the risk of relapse for children receiving 6-MP and MTX in the morning 
[29, 30]. This was the most successful chronotherapy trial and, consequently, evening 6-MP dosing 
is now the accepted standard of care for children with ALL. 
Chronochemotherapy has also improved anti-tumor effect in the treatment of metastatic 
colon cancer. The anti-metabolite 5-fluorouracil (5-FU) is commonly delivered by flat rate 
infusion. Despite the constant infusion rate, the mean plasma 5-FU concentration fluctuated over 
time [31]. Studies have identified rhythmic activity of the enzymatic target of 5-FU, thymidylate 
synthase [32], and an anti-phase rhythm in dihydropyrimidine dehydrogenase (DPD), an enzyme 
involved in catabolism of 5-FU [33]. Before applying this knowledge to the treatment of patients, 
a mouse study demonstrated daily rhythms in toxicity to the maximal 5-FU dose, correlating with 
DPD activity [34]. Metastatic colorectal cancer patients received constant infusions of 5-
fluorouracil (5-FU), leucovorin and oxaliplatin, or a chronomodulated delivery of those three drugs 
for 5 consecutive days per cycle. Chronomodulated delivery consisted of oxaliplatin 
administration for 11.5 hours (1015 to 2145) with peak delivery at 1600 hours, followed by 
[12] 
 
delivery of 5-FU and leucovorin from 2215 to 0945 hours, with peak delivery at 0400 hours. The 
chronomodulated delivery schedule increased the rates of grades 3 and 4 nausea and vomiting and 
caused a 4-fold increase in peripheral neuropathy compared to constant infusion. However, 
chronomodulated therapy caused lower rates of grades 3 or 4 mucositis, which is a major dose-
limiting toxicity for this treatment protocol. The median overall survival of all patients was 4.1 
months longer for chronomodulated vs constant infusion schedule patients (19 vs 14.9 months, p 
= 0.03;[35]). Despite the success of this trial, as well as the 329 citations of this article, 
chronomodulated therapy is not common practice in the treatment of colorectal cancer patients.  
Chronotherapy with other chemotherapeutics has been successful in the treatment of 
ovarian cancer patients. Delivery of doxorubicin in the morning (0600 h) and cisplatin in the 
evening (1800 h) was able to improve clinical outcomes in the treatment of advanced ovarian 
cancer. A clinical trial of 37 patients with stage III or IV ovarian cancer treated patients with 
doxorubicin at 0600 h (Schedule A) or 1800 h (Schedule B) followed by cisplatin 12 hours later. 
Patients receiving doxorubicin in the evening and cisplatin in the morning (Schedule B) 
experienced greater bone marrow toxicity, leading to more dose reductions and/or treatment delays 
compared to patients on Schedule A. Patients on Schedule A had a 4-fold increase in 5-year 
survival compared to Schedule B (44% vs 11%; [36]). This approach makes it more difficult to 
examine the chronotherapeutic benefits of each individual drug. However, this application of 
chronotherapy is more realistic and applicable to other cancers in the future because most cancers 
are treated with multiple agents simultaneously.  
Chronomodulation in the delivery of a variety of chemotherapeutic medications which act 
by many different mechanisms. And yet, all have been put to better use by delivering these drugs 
at a particular time of day. The mechanisms of action of these drugs may influence the outcomes 
[13] 
 
of chronotherapy, but it is also likely that rhythms within the patient’s body are influencing the 
activity and efficacy and toxicities of these medications. Blood flow changes with time of day [37] 
which may influence delivery of the drug to the tumor. Drug metabolism by liver enzymes, like 
cytochrome P450, changes across the day [37]. Elimination of the chemotherapy from the tumor 
and the body can also change with time of day. All of these rhythms outside of the tumor, but 
inside the body may influence how tumors respond to chemotherapy and how healthy tissues 
respond, as well. Some of the chronotherapy examples given above demonstrated reduced toxicity 
at a particular time of day because the biological rhythms of the patient were “out of sync” with 
the rhythms of the tumor. Additionally, great improvements in chemotherapeutic outcomes can be 
made by reducing toxicity alone; if patients have reduced toxicity at a high dose, patients can stay 
on that higher dose longer and have fewer treatment delays. In some cases, the anti-tumor effect 
of the chemotherapy may not change during the day, but chronotherapy still provides an advantage 
in these situations. In this thesis, the focus is on cell-intrinsic anti-tumor efficacy of TMZ. We have 
demonstrated changes in tumor sensitivity to TMZ using our model of glioblastoma in vitro. Future 
studies may optimize this treatment response further by taking into account the daily rhythms in 
toxicity.  
Rhythms within the tumor and within the patient can influence chemotherapy treatment 
outcomes. These rhythms exist at the levels of individual cells all the way up to human behavior. 
In order to achieve the greatest improvement in outcomes following treatment with chemotherapy, 
we must understand the daily rhythms within the human body.  
Links between Circadian Disruption and Cancer in Humans 
[14] 
 
The literature supporting the connection between shift work and the risk of developing 
cancer has provided some strong correlations, but none have definitively demonstrated that 
performing shift work causes cancer.  
Breast cancer risk is greater in nurses who worked the night shift for at least 20 years, 
using data from the Nurses’ Health Study [38]. A study conducted in Norway also demonstrated 
an increased risk of the development of breast cancer in nurses working the night shift for at least 
30 years [39]. A recent study demonstrated an increased risk of breast cancer development in 
female mice subjected to a chronically shift light schedule [40], lending further support to this 
shift work-breast cancer connection. Studies demonstrating changes in hormone regulation in 
correlation with light-at-night and disrupted sleep patterns are thought to underlie the increased 
incidence of hormone-related cancer, like breast cancer [41]. Additional epidemiological studies 
support the claim of a correlation between night shift work and an increase in the risk of breast 
cancer [42, 43].  As a result, the WHO lists shift work as a potential carcinogen. 
The correlation between disrupted circadian rhythms due to night shift work and cancer 
are not limited to breast cancer. Risk of developing and dying from lung cancer was increased 
among nurses working rotating night shift work for greater than 15 years [44-46]. The risk of 
developing skin cancer was also higher in night shift workers [47]. The risk of developing 
prostate cancer was higher in long-term (>28 years) night shift workers in Spain [48]. 
Researchers in Washington state interviewed 1101 ovarian cancer patients about their work 
schedules and found a higher rate of the development of invasive or borderline ovarian cancer 
for women doing shift work (24% and 48% increased risk, respectively; [49]). These 
epidemiological studies demonstrate that the correlation between shift work and cancer goes 
beyond sex, hormone regulation and breast cancer biology. Chronodisruption may increase the 
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risk of cancer development through basic biological principles that are common among a variety 
of cancers. 
Inconsistencies in the definition of shift work have led to some controversy over the 
validity of these epidemiological studies. A major problem contributing to the inconsistency 
among studies is the loose definition of shift work. Some studies focus on people who have 
worked the night shift. One caveat to this type of study is the assumption that night shift workers 
are awake during daytime hours on non-work days, experiencing extreme social jet lag on a 
regular basis. These studies rarely acknowledge the possibility that long term (>15 years) night 
shift workers change their entire schedules to accommodate their night shift work schedule, 
spending every night awake and every day asleep. Other studies look at employees working 
rotating shift schedules, which provides documented evidence of chronically changing rest-
activity schedules. In both cases, workers are exposed to light at night. Several studies were able 
to demonstrate a specific link between exposure to light-at-night and breast cancer by 
demonstrating lower rates of breast cancer in blind women [50, 51].  Another possible cause of 
increased cancer risk is the higher risk of sleep disruption among night shift workers, but little 
evidence exists to support this hypothesis. Although many studies have been conducted across a 
variety of types of employment, the specific exposure(s) of shift work that could potentially 
increase the rate of tumorigenesis remain unknown. 
The link between shift work and cancer was further called into question by 
epidemiological studies that have demonstrated no evidence for increased cancer risk among 
long-term night shift workers. For example, male chemical workers in Germany and female 
textile rotating shift workers in China did not have higher rates of developing prostate or breast 
cancer, respectively. Despite the doubts raised by inconsistencies in analytical methods, shift 
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work definitions and differences in outcomes between studies, the World Health Organization 
recognizes night shift work as a potential carcinogen (class IARC 2A carcinogen) [52].  
All of the examples listed above draw a link between disrupted circadian rest-activity 
rhythms and tumorigenesis. Additionally, a link between disruption of daily patterns of activity 
and response to therapy exists. Colorectal cancer patients with significantly disrupted circadian 
rhythms had a substantial reduction in median overall survival (11.9 months) compared to 
patients with intact circadian rest-activity rhythms (21.6 months; [53]). These data suggest that 
the circadian clock is involved in cancer progression, and possibly response to therapy, in 
addition to its contribution to development of cancer. 
Circadian Rhythms in Mammals 
We experience many rhythmic biological processes during an ordinary day. We are 
aware of some, like the sleep-wake cycle, but other rhythms are happening inside our bodies, 
unbeknownst to us. Oscillations in physiology and behavior that repeat approximately once per 
24 hour cycle are known as circadian rhythms. These oscillations occur in a large variety of 
organisms with obvious behavioral rhythms in humans, mice and many other species. These 
rhythms exist at the level of most individual cells within the human body. The molecular clock 
that drives cell-autonomous rhythms will be described in greater detail in a later section. These 
rhythms exist in the absence of external cues, but are influenced by environmental stimuli.  
The suprachiasmatic nucleus (SCN), the master pacemaker, is located in the 
hypothalamus. It responds to external cues from the environment and coordinates peripheral 
clocks within the body [54]. Mammals are able to entrain to external light cues via signals sent to 
the SCN. In the context of chronobiology, entrainment can be defined as the alignment of the 
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period and phase of a circadian system to the period and phase of an external rhythm (e.g. light 
cycles). Any external cue capable of entraining the clock is known as a zeitgeber (“time-giver”) 
[54]. In chronobiology, the abbreviation ZT is used, accompanied by a number which indicates 
the length of time that has passed since the organism has been exposed to the zeitgeber, or 
external cue. In many cases, the onset of light is a zeitgeber used to entrain organisms. In this 
thesis, the abbreviation ZT0 will indicate the time lights turn on and ZT12 will indicated the time 
lights turn off. Entrainment to an external signal can change the period or phase of the 
oscillation, but is not responsible for creating the oscillation. A true circadian rhythm is driven 
from within the organism, completely independent of external stimuli. The circadian clock exists 
and exerts its regulation of daily processes at many levels, including individual cells.  
Circadian rhythms exist at many levels and in a variety of physiological processes, but 
they all have a few common characteristics. Every circadian oscillation has a peak (maximum 
level reached in the oscillation) and a nadir (lowest point within the oscillation). The length of 
time it takes to complete one cycle, also known as the period of oscillation, is usually close to 24 
hours. The phase of the oscillation is the instantaneous state within a period. In the studies 
described in this thesis, the circadian oscillation of clock gene expression is divided into 4 
phases: peak, falling, trough and rising (see Figure 1.1).  
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Figure 1.1. Four phases of circadian oscillation in gene expression. 
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Conservation of the molecular clock across organisms 
 At all levels of the Tree of Life, survival is achieved by the organisms that are able to 
adapt to their environment. There is a common understanding that environments change over 
long periods of time. However, what is often overlooked is the fact that environmental changes 
can occur quite rapidly and often do so in a cyclical manner. If you have ever endured the 
blistering heat of a summer day in Phoenix, Arizona, and bundled up in a coat the following 
night, you understand that within a single day, your environment can change dramatically. You 
can also anticipate the need for a tank top to prepare for the heat of the following day. The 
development and conservation of a circadian clock is a way for organisms to anticipate and adapt 
to cyclical changes in their environment.  
 Although environmental rhythms exist on many time scales (lunar, tidal, seasonal), we 
will focus on daily rhythms for the purpose of informing this introduction. The word “circadian” 
comes from two latin words: “circa”, meaning about, and “dies”, meaning day. Thus, circadian 
rhythms are oscillations that complete a single cycle in approximately 24 hours. The most 
obvious example of a daily rhythm, at least at our current latitude, is the day-night cycle. These 
oscillations in availability and intensity of sunlight generate rhythms in temperature, both of 
which are external cues that organisms can entrain to. Entrainment means that the internal clock 
within the organism aligns itself with the daily cycles of the environment. For a variety of 
organisms, daily rhythms in availability of resources, like food, or the activity of predators 
require that organisms align themselves to these rhythms to ensure survival. 
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 The leaves of plants change position on a daily basis to accommodate exposure to 
sunlight for photosynthesis. The scientific literature describing daily leaf movements dates back 
to 1729, when a French astronomer, de Mairan, described daily rhythms in leaf movements that 
continued, even in constant darkness [55]. A variety of other organisms also have daily rhythms 
in response to daily oscillations in resources, like sunlight. 
The cyanobacterium Synechococcus has an internal clock that drives circadian rhythms 
in cell division, amino acid uptake, nitrogen fixation, photosynthesis, carbohydrate synthesis and 
respiration [56, 57]. Temporal separation of mutually exclusive intracellular processes, like 
nitrogen fixation and photosynthesis, is required to prevent the oxygen used for photosynthesis 
from blocking the activity of the nitrogenase enzyme [56].  
 The ways in which different organisms utilize circadian rhythms may vary, but they share 
common elements in the internal clocks that drive their anticipatory rhythms to adapt to the local 
environment. Regulation of gene transcription exists at the core of the internal clocks of 
organisms spread across phyla. Positive elements induce gene expression of clock-controlled 
genes (CCGs), creating a rhythmic expression of gene products, thus creating rhythms in cellular 
processes. Among the CCGs produced, some subset of proteins will provide negative feedback 
on the positive element to reduce transcription of CCGs and create a rhythm [56]. The structures 
and specific regulation of these common clock elements are not similar across bacteria, fungi, 
plants, invertebrates and mammals. However, the general structure of the molecular clocks is 
similar. Among mammals, there are highly conserved circadian genes. These will be described in 
the next section.  
The Mammalian Molecular Clock 
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Within most mammalian cells, there is a molecular clock regulating daily intracellular 
activities. The core of this molecular clock is a transcription-translation feedback loop. 
Transcription factors BMAL1 and CLOCK form a heterodimer and bind E-box sequences within 
gene promoters. This heterodimer activates expression of the downstream gene, which is known 
as a clock-controlled gene (CCG). The protein products of CCGs play important roles in a 
variety of cellular processes, including but not limited to metabolism, cell cycle regulation and 
DNA repair. Among the CCGs, the Period (PER1/2/3) and Cryptochrome (CRY1/2) proteins exit 
the nucleus and dimerize in the cytoplasm. Period proteins undergo casein kinase I (epsilon or 
delta)-mediated phosphorylation and re-enter the nucleus to inhibit further transcriptional 
activation of the BMAL1-CLOCK heterodimer. After providing negative feedback on the 
BMAL1-CLOCK dimer, the PER/CRY protein complex gets degraded, allowing the BMAL1-
CLOCK dimer to start activating transcription of CCGs again. This constitutes the core 
transcription-translation feedback loop. This loop is reinforced by a stabilizing loop, consisting 
of an activator, ROR-alpha, and a repressor, REV-ERB alpha, which act on the R-response 
element within the Bmal1 promoter. Transcriptional activation of Rora and Rev-Erb alpha are 
regulated by the BMAL1-CLOCK dimer. Together, RORA and REV-ERB alpha regulate 
expression of Bmal1, creating a circadian oscillation in Bmal1 expression that is anti-phase to the 
expression of clock-controlled genes ([58]; Figure 1.2). To track daily oscillations in the core 
clock, scientists have developed luciferase reporters of transcriptional activation of core clock 
genes. In this thesis, we have made use of the luciferase reporters Bmal1::dLuc and Per2::dLuc 
[59] to track daily oscillations in circadian clock gene expression in our model of mesenchymal 
GBM.  
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Figure 1.2: Mammalian molecular clock (adapted from Gallego and Virshup, 2007).  
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Bmal1 disruption abolishes circadian rhythms 
Bmal1 is a unique component of the core molecular clock because it is the only gene 
within the core clock whose deletion leads to loss of cellular rhythms in clock gene expression 
and loss of locomotor rhythmicity in constant darkness [60]. Deletion of any other component of 
the core clock is insufficient to disrupt circadian oscillations because there are redundant 
paralogs that can compensate for their role in the molecular clock in their absence. In many 
studies, deletion of both Clock and Npas2, or Cry1 and Cry2, or Per1 and Per2 are necessary for 
disruption of circadian rhythms [61-63]. Many studies have demonstrated loss of daily rhythms 
in clock gene expression in Bmal1 knockout cells or tissues [60, 64, 65]. Only one study 
demonstrates the rescue of behavioral rhythmicity in Bmal1 knockout mice by constitutive 
expression of Bmal2 [66]. However, in this same study, constitutive Bmal2 expression was not 
sufficient to restore rhythmic clock gene expression in SCN or lung tissue ex vivo [66]. In our 
study, we take advantage of the unique lack of molecular redundancy of Bmal1.  We take 
advantage of CRISPR-mediated disruption of Bmal1 expression to efficiently disrupt the 
molecular clock.  
Molecular connections between circadian clock and cancer 
Many studies in mammalian cells have described a connection between the core circadian 
clock and cancer. Several proteins of the core clock have been characterized as tumor 
suppressors, many of them interacting with key players in the cellular response to DNA damage 
and regulation of cell cycle progression. The circadian clock also exerts its influence on cell 
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cycle regulation, and DNA damage response by creating daily oscillations in the expression of 
clock-controlled genes.  
Characterization of core clock genes as tumor suppressors 
Several core clock proteins have been characterized as tumor suppressors through genetic 
manipulations in mouse models and cell culture. Mice expressing a mutant form of PER2 were at 
increased risk of developing radiation-induced lymphoma than wild type mice [67]. Mouse colon 
carcinoma C26 cells expressing Bmal1-targeted shRNA had a proliferation rate 36.4% higher 
than control cells 5 days after plating [68]. Overexpression of Bmal1 in the human colon cancer 
cell line HCT116 led to enhanced sensitivity to oxaliplatin treatment and greater apoptosis in 
vitro.  RNAi-mediated knockdown of Bmal1 in human colon carcinoma cell line HCT116 led to 
increased growth rates of subcutaneously implanted tumors in nude mice [69], demonstrating a 
cell-intrinsic role for Bmal1 in regulating tumor growth in vivo. Overexpression of Per1 or Per3 
led to reduced growth rates and increased rates of apoptosis in vitro [70, 71]. Cry1/2 double 
knockout increased UV-induced apoptosis in P53 knockout mouse embryonic fibroblasts by 
inducing expression of the pro-apoptotic tumor suppressor P73 [72]. Together, these data 
demonstrate a role for the molecular clock in regulating proliferation and apoptosis in a manner 
consistent with tumor suppressor function. 
Direct interactions of core clock proteins with other proteins, influencing DDR and cell cycle 
regulation 
In response to DNA double strand breaks, ATM kinase phosphorylates downstream 
targets to signal DNA repair and activation of a cell cycle checkpoint. By phosphorylating Chk2, 
ATM is able to activate the checkpoint pathway, leading to cell cycle arrest in response to DNA 
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damage. Direct interactions of PER1 and PER3 with ATM and Chk2 have been demonstrated. 
Overexpression of PER1 leads to increased phosphorylation of Chk2, causing increased 
activation of the cell cycle checkpoint. PER1 knockdown leads to reduced phosphorylation of 
Chk2 after DNA damage [70]. This is the result of an artificial overexpression of exogenous 
Per1, but it suggests an important role for PER1 in modulating the level of ATM-Chk2 signaling 
following DNA damage. Per1 mRNA and protein levels oscillate in most tissues. PER1 may 
mediate daily variations in response to DNA damage.  
Following single strand DNA breaks, the ATR-CHK1 pathway is activated. Activated 
ATR phosphorylates and thus activates Chk1, which leads to cell cycle arrest at the G2-M 
transition [73]. Following overexpression of Timeless in HEK293T cells, immunoprecipitation 
assays demonstrate interaction of Timeless with Chk1 and the ATR-ATRIP complex. 
Knockdown of Timeless causes a reduction in Chk1 phosphorylation, demonstrating a role for 
Timeless in regulating the degree of Chk1 phosphorylation following activation of the replication 
checkpoint pathway [74].  Timeless forms a complex with timeless interacting protein (Tipin) to 
protect cells from DNA damaging agents, like ionizing radiation and inducers of replication 
stress [75]. The Timeless-Tipin complex stabilizes replication forks and aids in homologous 
recombination by maintaining cohesion of the sister chromatid [76]. The role of Timeless in the 
mammalian circadian clock is unknown, but it is expressed in a variety of tissues and interacts 
with proteins involved in cell cycle regulation and DNA damage response. 
Core clock protein cryptochrome1 has been shown to interact with ATR to regulate the 
ATR-CHK1 checkpoint pathway, creating circadian oscillations in repair following UV-induced 
DNA damage. CHK1 and P53 phosphorylation are highest one hour after UV-induced DNA 
damage at ZT12 and at their nadir at ZT24 in NIH3T3 cells, corresponding to the peak and nadir 
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if CRY1 expression, respectively [77]. Similar rhythms in CRY1 expression and oscillations in 
ATR activity were observed in wild type mouse embryonic fibroblasts (MEFs). CRY1 
knockdown and Cry1/2 double knockout (DKO), but not CRY2 knockdown, abolished rhythms 
in ATR-mediated phosphorylation of Chk1, but continue to activate the ATR-mediated DNA 
damage checkpoint [77]. Thus, CRY1, but not CRY2, regulates the rhythmic DNA damage 
response through interactions with the ATR-Chk1 pathway.  
Circadian regulation of molecular processes via clock-controlled genes 
Clock-controlled genes are the outputs of the molecular clock. Several of these genes, 
whose transcription is regulated by the core transcription-translation feedback loop (TTFL), play 
important roles in cancer-related molecular pathways. The nucleotide excision repair protein, 
XPA, is the rate-limiting step in repair of UV-induced DNA damage. XPA protein levels 
oscillate throughout the day, reaching their peak levels at night.  Base excision repair activity 
reaches its peak near the time of peak XPA expression [78]. Sancar and colleagues have 
demonstrated a link between DNA repair and skin cancer based on these findings [79].  
Cell cycle regulation is also under the influence of the molecular clock, due to daily 
oscillations in the expression of clock controlled genes Wee1 [80], CyclinD1, and c-Myc [67]. 
Nuclear kinase Wee1 phosphorylates Cdk1, thus inhibiting cell cycle progression into mitosis. 
Rhythmic mRNA expression is observed during murine liver regeneration following partial 
hepatectomy. Cry1/2 double knockout mice experienced impairment in liver regeneration due to 
a reduced rate of progression from S phase to mitosis. In the Cry1/2 DKO livers, wee1 
expression was elevated, while mRNA levels were reduced for cell cycle regulators that would 
promote entry into mitosis (e.g. Cdc2, CyclinB1). In Clock mutant mice, wee1 expression is 
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reduced, demonstrating circadian regulation of wee1 [80]. Transcription factor c-Myc has 
multiple E boxes within its promoter and its mRNA levels oscillate in wild type mouse livers. In 
homozyogous Per2 mutant mouse livers, c-myc mRNA expression is expressed at much higher 
levels compared to wild type mouse liver. CyclinD1 mRNA expression oscillated in a circadian 
pattern in wild type mouse livers reaching its peak in the early night (ZT 14). This circadian 
oscillation was not present in mPer2 mutant mouse livers, suggesting circadian regulation of 
CyclinD1 expression [67].  
Links between the molecular clock and apoptosis 
 Through genetic manipulation of clock genes, the molecular clock has been linked to the 
apoptotic pathway. Bmal1 knockdown in the C26 colon cancer cell line reduced etoposide-
induced apoptosis from 29.4% to 11.2% [68]. Similarly, Per1 knockdown in the HCT116 colon 
cancer cell line reduced IR-induced apoptosis rates from 37% to 13% [70]. Gery and colleagues 
also increased IR-induced apoptosis by overexpressing Per1 in HCT116 cells [70]. 
Overexpression of Per2 in lung and breast cancer cell lines increased the proportions of 
apoptotic cells without inducing DNA damage. These Per2 overexpressing-cells had 
downregulated expression of anti-apoptotic genes Bcl-XL and Bcl2, in addition to upregulation of 
pro-apoptotic gene Bax [81]. Overexpression of Per3 in HeLa cells increased caspase-3 and 
PARP cleavage, indicating increased activation of apoptosis, in the absence of DNA damaging 
agents[71]. Together, these data indicate that multiple core clock proteins promote apoptosis.  
 This body of literature demonstrates important roles for core clock proteins in regulating 
cell proliferation, response to DNA damage and apoptosis. In some cases, these roles are carried 
out indirectly through BMAL1-CLOCK-mediated transcriptional activation of key regulators of 
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these cellular pathways. Some studies have demonstrated direct protein-protein interactions of 
core clock proteins with regulators of cell cycle progression and DNA damage response. 
Increasing our understanding of the regulation of all of these processes directly or indirectly by 
the molecular clock will provide many opportunities for enhancing treatment outcomes using 
drugs, especially chemotherapies, targeting these cellular pathways.  
Conclusions and objectives of the dissertation 
Through regulation of transcription and direct protein interactions, the molecular clock is 
capable of influencing a variety of cellular processes related to tumorigenesis and tumor 
response to chemotherapies. This thesis seeks to harness the power of the circadian clock to 
target the tumor with chemotherapy at the time of day when the tumor is least able to defend 
itself. As discussed in the introduction, TMZ has already provided a significant advancement in 
clinical outcomes for glioblastoma patients. Its short half-life in the tumor makes TMZ an 
excellent candidate for further optimization of anti-tumor efficacy through chronotherapy. We 
use circadian research tools to learn more about the relationship between the circadian molecular 
clock and the response of glioblastoma to TMZ therapy. By correlating the phase of circadian 
clock gene expression with daily rhythms in DNA repair and activation of apoptosis, we can 
predict the timing of optimal sensitivity in future cultures or tumors. By disrupting the molecular 
clock through deletion of Bmal1 (Arntl) we are able to identify the contributions of the molecular 
clock to DNA damage response. This thesis is the first application of chronotherapy to brain 
tumors, which demonstrates the versatility of this technique. This will hopefully encourage other 
researchers to consider chronotherapy in the future. Although many other cancers are not treated 
with TMZ, many anti-cancer drugs induce DNA damage. By focusing this thesis on the tumor’s 
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response to TMZ-induced DNA damage, we are providing valuable information that can be 
applied to other anti-cancer therapies, including ionizing radiation. 
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Chapter 2: Characterization of circadian rhythms in gene expression and 
TMZ sensitivity in U87 glioma cell line in vitro 
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Abstract 
Glioblastoma (GBM) is the most common and aggressive malignant primary brain tumor 
in adults. Current therapy involves surgical resection, radiotherapy with concomitant 
temozolomide (TMZ) chemotherapy, and 6 cycles of adjuvant TMZ chemotherapy. Despite 
initial response to these treatments, GBM very frequently recurs. Our goal is to improve upon the 
efficacy of TMZ treatments. Previous studies have demonstrated improved clinical outcomes in 
cancer patients by timing the delivery of chemotherapy to biological rhythms, a method known 
as chronotherapy. To investigate the role of cell-intrinsic circadian rhythms in modulating the 
response to TMZ, we developed an in vitro system to track rhythms in gene expression with 
luciferase reporters and measure TMZ response throughout the day. Using an established GBM 
cell line, we were able to observe circadian rhythms in clock gene expression and rhythmic 
sensitivity to TMZ in vitro. TMZ sensitivity, as measured by a cell survival assay, showed 
rhythms with peak survival consistently correlating with the peak of Per2 expression across two 
independent experiments. In a single preliminary experiment, we have also demonstrated a 
rhythm in phosphorylation of H2AX, reaching the highest percent of phospho-H2AX positive 
cells at the time of peak Bmal1 expression. We used single cell gel electrophoresis to measure 
dose-dependent changes in TMZ-induced DNA damage. We also observed shifts in clock gene 
expression following TMZ treatment, suggesting that TMZ-induced damage resets the molecular 
clock. These preliminary data are the first to demonstrate circadian rhythms in TMZ sensitivity 
in a human glioblastoma cell line. The knowledge gained from the results of these preliminary 
experiments was applied to the design of future in vitro experiments to measure circadian 
rhythms in TMZ response in a murine astrocyte model of glioblastoma. 
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Introduction 
 Glioblastoma is the most common and aggressive malignant primary brain tumor in 
adults. Surgical resection, radiation and chemotherapy are able to lengthen survival, but tumors 
ultimately recur in most patients [82]. Temozolomide, a DNA alkylator, was the first 
chemotherapy to significantly lengthen survival in GBM patients [21]. Despite this advancement, 
median survival is still only approximately 15 months [83]. Development of new treatments is 
crucial for improving survival of future GBM patients, but the development of new therapeutics 
takes many years. Therefore, patients who are currently suffering from GBM cannot afford to 
wait for new treatments; we need to make sure we are providing optimal care with the therapies 
that are currently available.  
 One method of optimizing treatment outcomes is chronomodulation of chemotherapy. 
The delivery of chemotherapy according to biological rhythms, known as chronochemotherapy, 
has successfully increased survival and reduced toxicity for a variety of chemotherapies [30, 35, 
36, 84]. Chronochemotherapy has been applied to many cancer types, but our study is the first to 
apply it to brain tumors.  
 Before we tried chronotherapy in a mouse model of GBM, we wanted to learn about the 
cell intrinsic circadian properties of GBM cells. We used a human glioblastoma cell line, U87, to 
characterize circadian rhythms in gene expression and TMZ sensitivity in vitro. U87 cells are 
sensitive to TMZ treatment because they have hypermethylation of the MGMT promoter, which 
prevents expression of an enzyme known to provide resistance to TMZ-induced DNA damage 
[85]. Starting with a TMZ sensitive cell line, we were interested in testing whether the time of 
day of treatment would alter the sensitivity. The studies presented in this chapter are preliminary; 
many experiments were performed only one or two times. Even though the observations made 
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from these studies will not be published, they provided an early indication that circadian biology 
would impact TMZ responses and represent a critical stage in the development of the knowledge 
and skills that were required to perform the publishable studies in this thesis.   
Materials and Methods 
Cell Culture: The U87MG human glioblastoma cell line was purchased from American Type 
Cell Culture (ATCC). U87 cells were maintained at 37oC at 5% CO2 in CO2-buffered Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) 
(Gibco/Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco/Life 
Technologies, Carlsbad, CA). During bioluminescence recordings, lids were sealed with vacuum 
grease and cell cultures were maintained in HEPES-buffered DMEM supplemented with 10% 
FBS, B27 (1X; Gibco/Life Technologies, Carlsbad, CA), as previously reported [86]. All 
bioluminescent cultures were maintained at 34oC. U87 cells were used up to passage 8 for 
experiments. 
Temozolomide treatment of cultures: Temozolomide from Temodar capsules was dissolved in 
DMSO at a stock concentration of 100 mM and used at a concentration of 0.5 mM for 
experiments.  
Bioluminescence recordings in vitro: Light from clock-gene reporters (Bmal1::dLuc or 
Per2::dLuc) was detected in customized light-tight incubators (34°C) equipped with 
photomultiplier tubes (PMT) (HC135--11; Hamamatsu Corp.) [86-88] or with an ultra-sensitive 
Charge-coupled device (CCD) camera in a light tight box (Stanford Photonics; bin factor, 2; 1/f 
stop; open filter; Stanford Photonics, Palo Alto, CA). Bioluminescence was integrated every 6 
min over 4 –7 days in HEPES-buffered DMEM supplemented with 10% FBS, B27 (Life 
Technologies, Carlsbad, CA) and 0.1 mM D-luciferin (Xenogen, Alameda, CA). U87 cells plated 
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in the 96-well plate were cultured in 1% FBS instead of 10% FBS to prevent overgrowth in the 
dish during the 7 day experiment. 
 
Expression of Per2::dLuc and Bmal1::dLuc reporters: We performed lentiviral infections of 
pure astrocyte cultures using lentiviral reporter constructs expressing firefly luciferase driven by 
the mouse Bmal1 or (Bmal1::dLuc) [89, 90] or Period2 (Per2::dLuc) [59] promoters. Astrocytes 
were incubated with the viral particles for 48 h. Infected cultures were split and re-plated twice 
before the start of an experiment. 
 
Phospho-H2AX immunofluorescence staining and quantification: U87 cells plated on poly-d-
lysine-coated glass coverslips were fixed with 4% paraformaldehyde, washed, permeabilized 
with Triton-X-100, incubated with phospho-S139 H2AX primary antibody (Molecular Probes) 
for 3 hours at 37C, washed with 1x PBS, incubated with Alexa fluor 568 Donkey α mouse IgG 
(Gibco/Life Technologies, Carlsbad, CA) for 1 hour at RT. Then, stained with DAPI (4’,6’-
diamino-2-phenylindole) (Gibco/Life Technologies, Carlsbad, CA) and mounted on glass slides 
with Immu-mount (Thermo Scientific, Pittsburgh, PA). Nuclear staining intensity was quantified 
by two individuals blinded to treatment conditions using an ImageJ plugin. Staining was 
quantified across 5 fields of view per coverslip and averaged across two coverslips per treatment 
condition. The threshold for positive staining was set after the completion of staining 
quantification using a histogram of a TMZ-treated versus DMSO-treated.  
Counting DAPI-stained nuclei for cell survival assay: After fixation, U87 cells were 
permeabilized with Triton-X-100, then stained with DAPI for 10 minutes, then stoed in 1xPBS 
(Gibco/Life Technologies, Carlsbad, CA). Nuclei were counted using an ImageJ plugin. Two 
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independent counters counted 5 representative images and achieved similar results, counting the 
same number of cells within 10% per field of view.  
Single Cell Gel Electrophoresis (Comet assay): U87 cell cultures were treated with vehicle or 
TMZ for 6 hours, then trypsinized and counted. Cells were added to Comet Assay Low-Melt 
Agarose (Trevigen, Gaithersburg, MD), and spread on Comet Assay slides (Trevigen, 
Gaithersburg, MD). Agarose gel-suspended cells were lysed in ice cold lysis buffer (Trevigen, 
Gaithersburg, MD) for 30 min. Slides were exposed to 35V in a gel electrophoresis apparatus. 
Slides were washed in water and ethanol, then stained with ethidium bromide (Sigma, St. Louis, 
MO). Images were acquired on a fluorecescence microscope. Images were quantified by 
CometScore software, measuring a minimum of 50 cells per treatment group. 
Results 
Circadian rhythms in clock gene expression in U87 glioblastoma cells in vitro 
 The human U87MG glioblastoma cell line (U87) had daily oscillations in clock gene 
luciferase reporters (Figure 2.1A). The time it takes to complete one oscillation, known as the 
period, was measured using 3-7 days of photomultiplier tube (PMT) recordings of either Per-Luc 
or Bmal1-Luc expression for each dish.  The mean periods for Per2-luc and Bmal1-luc U87 
recordings were 23.6 h and 25.7 h, respectively (Table 2.1). As seen in other cell types, the 
Per2-luc and Bmal1-luc bioluminescence oscillate in anti-phase (Figure 2.1A), with an average 
phase difference of 12.1 h between Per2-luc peak and Bmal1-luc peak on Day 2 of each 
recording. For the purposes of our studies, we consider the differential effects of treatments at 
four times (trough, rising, peak, or falling phases) in the daily Bmal1-luc expression rhythm 
(Figure 2.1B). 
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Table 2.1. Characterization of circadian rhythms in clock gene expression in U87 cells in 
vitro. 
Circadian characterization of bioluminescence recordings Mean ± SEM 
 
N 
Period of Clock Gene Expression (Per2 and Bmal1 reporters) 24.5 ± 0.8 h 5 
Period of Per2-luc Expression 23.6 ± 0.5 h 2 
Period of Bmal1-luc Expression 25.7 ± 1.7 h 3 
Time between Per2 and Bmal1 peaks on Day 2 of recording 12.1 ± 1.6 h 2 (Pairs) 
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Figure 2.1. Circadian oscillations in clock gene expression in U87 cells in vitro. A) 
Representative traces from Per2-luc and Bmal1-luc bioluminescence reporters. B) 
Representative trace with circadian phases labeled: trough, rising, peak and falling. 
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Circadian rhythms in TMZ sensitivity in U87 glioblastoma cells in vitro 
 Per2-luc-expressing U87 cells were plated in a 96-well plate and immediately placed in a 
light tight box for bioluminescent recording with a Charge-coupled device camera. 
Bioluminescence images were captured over time. Wells were treated in triplicate with 0.5 mM 
TMZ or vehicle (DMSO) for 6 hours, with each set of wells treated at different phases of Per2-
luc expression: trough, rising, peak or falling phase. After 5 days of recording, the cells were 
fixed and stained with DAPI. In order to measure TMZ cytotoxicity, DAPI-stained nuclei were 
counted in three high powered fields per well. The survival of the TMZ-treated cells was 
expressed as a fraction of the number of cells counted in the DMSO-treated wells. In two 
independently plated experiments, there was a rhythm in the survival fraction (Figure 2.2C&D). 
Across the two experiments, there was a consistent correlation between lowest survival fraction 
and TMZ treatment at the trough of Per2-luc expression.  
To determine whether these rhythms in cell survival could be attributed to rhythms in the 
DNA damage response, we measured phosphorylation of H2AX, an early step in sensing DNA 
damage [91]. U87 cells were plated on coverslips and treated with 0.5 mM TMZ or vehicle at 
different phases of Bmal1-luc expression: trough, rising, peak or falling phase. Eighteen hours 
after treatment, cells were fixed and stained for phospho-H2AX and DAPI. The number of 
phospho-H2AX positive nuclei was counted and divided by the total number of nuclei per field 
of view. Percent of phospho-H2AX positive staining was measured across 5 fields of view and 
two replicate coverslips per treatment group. The Per2-luc reporter corresponded closely with 
the rhythm we identified in cell survival, but we wanted to assess the utility of both Per2-luc and 
Bmal1-luc reporters in these studies. Based on the consistent anti-phase relationship established 
by early characterization of Per2-luc and Bmal1-luc expression in U87 cells, we chose to use the 
[42] 
 
Bmal1-luc reporter in this experiment to address the basis for the rhythm in TMZ response. A 
rhythm in phospho-H2AX positivity was evident with a peak response in those cells treated at 
the peak of Bmal1-luc expression (Figure 2.2E&F), which coincides with the trough of Per2. 
These data demonstrate a rhythm in sensing of TMZ-induced DNA damage in U87 cells that is 
in phase with the rhythm we have observed in cell survival. Moreover these data indicated that 
both of our reporters behaved as expected and provided reliable readouts of circadian time. 
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Figure 2.2. Rhythms in cell survival and DNA damage response to TMZ. Representative 
traces of Per2-luc recordings of U87 cell cultures treated at different phases of Per2-luc expression 
for two independent experiments (A & B). Surviving fraction of cells for each independent 
experiment were calculated by dividing the number of cells in TMZ-treated wells to vehicle-treated 
wells at each treatment time point (C&D). E) Bmal1-luc expression from reporter dish plated in 
parallel with wells treated with TMZ and stained for phospho-H2AX. F) Results of chronotherapy 
of U87 cell cultures fixed and stained for H2AX phosphorylation in TMZ-treated (red) and 
DMSO-treated (black) wells (n= 1). 
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Temozolomide-induced DNA damage measured by comet assay 
 The rhythm we observed in TMZ-induced H2AX phosphorylation could be due to 
rhythms in the number of double strand breaks (DSBs) created after TMZ treatment or a rhythm 
in the DNA damage response to an equal number of TMZ-induced breaks created at all times of 
day. We aimed to test whether DNA damage by TMZ varies with time of day using single cell 
gel electrophoresis (comet assay)[92]. In the absence of DNA damage, ethidium bromide-stained 
nuclei travel through the gel as a discrete circle (Figure 2.3A, vehicle). However, a “comet tail” 
is formed after DNA damage by the faster movement of ethidium bromide stained DNA 
fragments (Figure 2.3B, 1000 µM TMZ). The extent of DNA damage can be quantified from 
fluorescence images of these comets using CometScore software and reported as the olive tail 
moment [93]. We measured the extent of DNA damage after 6 hours of treatment with vehicle, 
100, 500 or 1000 µM of TMZ (Figure 2.3C). Unfortunately, large standard deviations for the 
olive tail moments measured for each dose along the dose-response curve did not allow us to 
reliably distinguish between the amounts of damage induced by different doses of TMZ. 
Therefore, we were unable to use the comet assay to quantify DNA damage induced by a single 
dose of TMZ at different times of day.  
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Figure 2.3. Comet Assay reveals highly variable TMZ-induced DNA damage in U87 cells 
in vitro. A) Representative image of ethidium-bromide stained nuclei from DMSO-treated U87 
cells 6 hours after treatment. B) Representative image of an ethidium-bromide stained nucleus 6 
hours after TMZ-induced DNA damage. C) Quantification of a TMZ dose-response curve (0, 
100, 500, 1000 µM TMZ). Olive Tail Moment quantifies the extent of DNA damage induced at 
each dose of TMZ (Mean ± SD).  
[46] 
 
Treatment-induced phase shifts in Per2-luc rhythms in vitro 
 We observed shifts in the phase of Per2-luc expression after treating wells at different 
times of day in the cell survival assay described above (Figure 2). We chose to measure rhythms 
on Day 4 because all treatments included in this analysis were completed by the start of Day 4. 
We did not measure the timing of peaks on Day 5 because some Per2-luc traces damped out 
considerably by Day 5, making it difficult to identify peaks for all treated cultures. This 
dampening of Per2-luc amplitude on Day 5 is consistent with what we have previously seen in 
bioluminescence recordings in the absence of TMZ or vehicle treatments. Figure 4A shows 
TMZ-treated wells reached the Per2 peak earlier than the wells treated with DMSO during the 
same 6 hour time frame (yellow bar). The average timing of Per2 peak expression is expressed 
as hours after the start of Day 4, the day after treatment (Figure 4B). DMSO-treated dishes 
reached their Per2 peaks (black circle) at different times of day depending upon the timing of 
treatment on the previous day. TMZ-treated wells did not reach peak of Per2 expression at the 
same time on Day 4 as the DMSO-treated wells (Figure 4B). Relative to vehicle controls, we 
observed delayed Per2 peaks in wells treated with TMZ at the peak or falling phases of Per2 
expression. In contrast, wells treated at the trough or rising phases of Per2 expression had TMZ-
treated wells reaching the peak of Per2 earlier than vehicle controls. These data demonstrated 
treatment-induced shifts in the phase of Per2-luc expression. The direction of the TMZ-induced 
shifts was dependent on the Per2 phase at the time of treatment: treatments at peak and falling 
phases caused phase delays and treatments at the trough and rising phases caused phase advances 
in Per2 rhythms. This observation is important because repeated it shows that treatments 
delivered at the same time of day on two consecutive days could be delivered to cells at two 
different phases of clock gene expression. Therefore, these data represent an important 
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complicating factor to keep in mind in future experiments:  DNA damage-induced phase shifts in 
circadian clock gene expression may alter the way cells respond to treatment on subsequent days. 
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Figure 2.4. Direction of TMZ-induced phase shifts is circadian phase-dependent. A) 
Representative trace of TMZ-treated (red) and DMSO-treated (black) Per2-luc traces from U87 
cell cultures. Yellow bar represents 6 h exposure time to TMZ or vehicle. The timing of peak 
Per2-luc expression on Day 4 (one day after treatment; blue arrows) is earlier for TMZ-treated 
cultures than DMSO-treated cultures. B) The average timing of peak Per2-luc expression on Day 
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4 is reported for TMZ-treated (red rectangle) and DMSO-treated (black circle). Each graph 
represents wells treated at the same phase of Per2-luc expression on Day 3 (n = 1). 
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Discussion 
 Daily oscillations in expression of Per2-luc and Bmal1-luc reporters demonstrated that 
U87 cells have an intact molecular clock and that we can reliably measure its activity. Many 
human cancer cell lines that have been tested have failed to demonstrate rhythmic clock gene 
expression (Robert Dallman and John Hogenesch, personal communication). The anti-phase 
oscillations of Per2-luc and Bmal1-luc demonstrate canonical regulation of the molecular clock 
within the U87 cells. Therefore, these data demonstrate a functional clock within U87 cells, 
providing a cell-intrinsic mechanism by which TMZ sensitivity could change with time of day.  
 Preliminary data demonstrate circadian oscillations in TMZ sensitivity in U87 cells in 
vitro. The fraction of cells that survive TMZ treatment varies in a time of day-dependent manner. 
Across two independent experiments, we demonstrated that U87 cells have the lowest survival 
fraction, and therefore are the most sensitive to TMZ at the trough of Per2-luc expression. In a 
single preliminary experiment, we have demonstrated a circadian rhythm in phosphorylation of 
histone H2AX, with the greatest phosphorylation occurring at the peak of Bmal1 expression. 
This correlation with circadian clock gene expression is consistent with the results of our 
survival assay. As demonstrated in Figure 1A, Bmal1 reaches its peak at the time that Per2 
reaches its trough. Therefore, TMZ treatment at the peak of Bmal1/trough of Per2 results in the 
greatest amount of DNA damage sensing and the lowest survival. These data are consistent with 
data from Dulong and colleagues demonstrating greatest irinotecan sensitivity at Bmal1 peak in 
colon cancer cells [94]. Taken together, these preliminary data demonstrate greatest TMZ 
sensitivity of U87 cells at the peak of Bmal1 expression in vitro. Future studies should repeat 
these assays to assess reproducibility of these findings. Reproducing these findings in a different 
cell line would further strengthen the biological link between Bmal1 expression and TMZ 
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sensitivity. Furthermore, these studies demonstrate a cell-intrinsic rhythm governing response to 
TMZ, not simply a rhythm in drug metabolism or delivery to the tumor via rhythms of the host. 
The tumor cell-intrinsic nature of this rhythm creates an opportunity to manipulate the rhythms 
of the tumor to specifically enhance TMZ anti-tumor efficacy, without altering the sensitivity of 
the host. 
 The rhythms observed in phosphorylation of H2AX could be due to rhythms in the 
amount of TMZ-induced DNA damage or the cellular response to DNA damage. The comet 
assay is the most direct way to assess DNA damage. We have demonstrated that TMZ-induced 
DNA damage is greater than baseline DNA damage in vehicle-treated U87 cells using this assay. 
However, the high degree of variability within each sample limits the sensitivity of the comet 
assay. Since we are looking at low-amplitude changes, we need to use highly sensitive methods 
to detect and measure changes in the response of U87 cells to TMZ treatment. For these reasons, 
we chose not to use this method to determine whether there was a circadian rhythm in the 
amount of TMZ-induced DNA damage in future experiments. We were unable to determine 
whether the amount of TMZ-induced DNA damage oscillated in a circadian manner because we 
did not have a sensitive enough assay to quantify DNA damage.  Future studies might examine 
the early induction of H2AX phosphorylation as a proxy for DNA damage prior to the initiation 
of DNA repair. 
 We observed treatment-induced shifts in the phase of Per2-luc expression. If the DMSO 
treatments had not caused any phase shifts in Per2 rhythms, we would have seen the Per2 peaks 
occurring at the same time on Day 4 in all DMSO-treated wells. However, we saw the DMSO-
treated wells reaching peak of Per2 at different times on Day 4 due to treatment at different 
phases of Per2-luc expression. These shifts in the DMSO-treated wells could be explained by the 
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media change which occurred at the end of the 6 hour treatment window. In our lab, we have 
seen media changes, shifts in temperature and physical movement of dishes reset the rhythms of 
clock gene expression in other in vitro experiments (data not shown). What is more interesting is 
the timing of peak Per2 in the TMZ-treated wells relative to the vehicle-treated wells. If the 
media change, temperature change or movement of the 96-well plate were the only mechanisms 
underlying these phase shifts in Per2 rhythms, we would have seen shifts in the same direction in 
TMZ- and DMSO-treated wells. However, we saw TMZ-induced shifts away from vehicle 
control rhythms. The directionality of the phase shift was dependent upon the Per2 phase at the 
time of treatment. TMZ induces phase delays in Per2 rhythms when treating at Per2 peak or 
falling phases. In contrast, TMZ induces phase advances in wells treated at the Per2 trough or 
rising phases. These data are consistent with a study showing ionizing radiation-induced phase 
advances in Per2-luc rhythms in Rat-1 cells [95]. Following up on those findings, another paper 
presented a mathematical model where IR-induced activation of Chk2 led to premature 
degradation of PER proteins, thus advancing the phase of the clock [96]. A recent publication 
presented Hausp-dependent stabilization of Cry1 as the mechanism underlying ionizing 
radiation-induced phase advances in circadian rhythms in fibroblasts [97]. In the context of the 
literature, it seems likely that the phase shifts created in the TMZ-treated wells are due to TMZ-
induced DNA damage. In all of these papers, DNA damage only induces phase advances. In 
contrast, our preliminary study shows phase advances and delays relative to vehicle-treated 
controls. The published studies used ionizing radiation to induce immediate DNA double strand 
breaks (DSBs). However, our studies utilize a DNA alkylator, which indirectly leads to DSBs 
during failed mismatch repair [98]. Also, our study requires media change at the end of the 6 h 
TMZ treatment window, which could also induce phase shifts. We can be confident that the 
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phase shifts we see in the TMZ-treated dishes are not due solely to media change because the 
TMZ- and DMSO-treated dishes do not shift together in equal magnitude, or in the same 
direction. The added complication of media change-induced phase shifts may provide an 
opportunity for phase delays that are not possible in the published IR-induced phase advance 
studies. Alternatively, there may be unique aspects of the molecular clock in U87 cells that allow 
for phase delays. Also, it is important to recognize that our studies are preliminary. We would 
need to perform this experiment several more times to make sure these results are repeatable. 
Future studies would require treatments at shorter intervals to create a full phase response curve 
with TMZ and DMSO to identify the differences in phase shifts caused by each treatment 
condition. Extending these studies to other cell lines and other DNA damaging agents will help 
us understand which principles of DNA damage-induced phase shifts are universal across all 
DNA damaging agents and all cell lines possessing circadian rhythms. 
 The knowledge gained from these preliminary U87 in vitro studies guided the design of 
the studies that follow. We were able to optimize our protocol for luciferase reporter expression 
and bioluminescence recordings using U87 cell cultures. We established a relationship between 
the peak of Per2-luc expression and the greatest cell survival. This relationship was consistent 
with the rhythm we observed in phosphorylation of H2AX, showing a correlation between the 
phase of clock gene expression and TMZ sensitivity by two independent methods. Our 
observations of DNA damage-induced shifts in circadian rhythms made us keenly aware of the 
complexity of our model system. Therefore, in all future studies we chose to limit our in vitro 
experiments to single doses of TMZ per dish due to the DNA damage-induced rhythms we 
observed in these preliminary studies. The information we learned from these in vitro studies set 
the stage for the experiments we performed in our mouse model of mesenchymal GBM. The 
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results of these in vitro studies indicate cell-intrinsic circadian rhythms in gene expression and 
DNA damage response, which provides a strong rationale for further investigation into the cell-
intrinsic properties contributing to circadian rhythms in TMZ sensitivity. 
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Abstract 
The safety and efficacy of multiple cancer chemotherapeutics can vary as a function of 
when during the day they are delivered. This study aimed to improve the treatment of 
glioblastoma multiforme (GBM), the most common brain cancer, by testing the efficacy of the 
DNA alkylator Temozolomide (TMZ) on GBM in vitro and in vivo as a function of time of day. 
We found cell-intrinsic, daily rhythms in susceptibility of GBM tumor cells (mouse astrocytes 
deficient in NF1 and p53 signaling) to TMZ in vitro. The greatest TMZ-induced DNA damage 
response, activation of apoptosis and growth inhibition, occurred near the peak expression of the 
core clock gene Bmal1 in cultured GBM cells. Deletion of Bmal1 abolished rhythmic circadian 
clock gene expression and circadian rhythms in TMZ-induced activation of apoptosis and growth 
inhibition in GBM tumor cells in vitro. Taken together, these data suggest an important role for 
the core molecular clock in regulating the tumor cell-intrinsic response to TMZ-induced DNA 
damage. These results may be important broadly for how we design TMZ and other DNA 
damaging approaches to GBM treatment. 
Introduction 
Glioblastoma, a WHO grade IV astrocytoma, is the most common and aggressive 
malignant primary brain tumor in adults. Despite decades of research and many clinical trials, 
median survival is still only approximately 15 months [83]. Therefore, all opportunities to 
improve upon the current treatment outcomes should be pursued. 
For many years, surgical resection and radiation therapy were the standard of care. In 
2005, a landmark paper published in the New England Journal of Medicine demonstrated an 
increase in progression-free and overall survival with the addition of temozolomide (TMZ) 
chemotherapy [21]. Clinicians have tried a variety of TMZ treatment schedules to optimize 
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treatment, eventually settling on a 5-day course every 28 days to minimize toxicity [99, 100]. 
However, none of these studies took into account the time of day of TMZ administration. As an 
oral medication, it is easy to regulate the timing of treatment. TMZ has a blood plasma half-life 
of 1.8 h [101], in addition to a short half-life (1.7-2.6 h) within tumors in animal models of GBM 
[102, 103], making it an ideal candidate for chronotherapy.  
Oncologists have tested the efficacy and tolerability of chemotherapeutic agents at 
different times of day in a variety of cancer types. The administration of medications based on 
daily rhythms in biological processes is known as chronotherapy. Chronotherapy has increased 
5-year survival rates in acute lymphoblastic leukemia and ovarian cancer patients, and increased 
the objective response rate in colorectal cancer while simultaneously reducing toxicities [30, 35, 
36]. Despite successful therapeutic outcomes, chronotherapy has never been applied to the 
treatment of brain tumors. 
Our daily rhythms in sleep, hormone release, and many other physiological processes are 
driven by an internal circadian clock [54]. Molecular clocks exist within most cells to keep daily 
time at the cellular level. The core molecular clock includes two transcription factors, BMAL1 
and CLOCK, which activate transcription of downstream genes. Genes activated at different 
times of day by the BMAL1-CLOCK transcription dimer are known as clock-controlled genes 
(CCGs). Among those CCGs, the gene products of the Period family (Per1, Per2, Per3), and the 
Cryptochrome family (Cry1 and Cry2) provide negative feedback to block further transcriptional 
activation by the BMAL1-CLOCK dimer [104]. This feedback loop creates circadian oscillations 
in clock-controlled gene expression. A stabilizing feedback loop regulates transcription of the 
Bmal1 gene (Arntl), creating an oscillation in Arntl expression that is anti-phase to the clock-
controlled genes [105-107]. Loss of Arntl leads to loss of rhythms in individual cells, and rest-
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activity rhythms demonstrating the crucial role Bmal1 plays in regulating circadian function [60]. 
Our studies take advantage of the importance of Bmal1 to explore the contributions of the 
circadian clock to the response of glioblastoma to TMZ. 
Many links have been made between circadian clocks and cancer. Epidemiological 
studies have demonstrated that shift workers have a higher risk of developing cancer [47, 108], 
creating a correlation between disrupted clocks and tumorigenesis in humans. To build on this 
shift work-cancer link, scientists have recently demonstrated an increased risk of breast cancer 
development in female mice exposed to a chronically shifting light schedule [40]. Circadian 
rhythms in human physiology have also been linked to survival for colorectal and breast cancer 
patients [84]. Expression of circadian clock genes has been deregulated in a variety of cancer 
types, including gliomas [109-113]. At the molecular level, circadian clock proteins have been 
directly linked to DNA damage response. The circadian role of mammalian TIMELESS (Tim) 
remains unknown, but requirement of Tim for DNA damage checkpoint responses has been 
demonstrated through interactions with the ATR-Chk1, and ATM-Chk2 pathways [74, 77, 114-
116]. PER1 protein interacts directly with ATM and Chk2, enhancing activation of the 
checkpoint pathway [70]. PER3 also interacts with and enhances ATM-mediated 
phosphorylation of Chk2 [71]. Rhythmic expression of the base excision repair protein, XPA, 
creates daily rhythms in UV-induced DNA damage [78]. Circadian rhythms in transcription have 
been demonstrated for cell cycle regulators Wee1, c-Myc and CyclinD1 [67, 80]. We know 
circadian regulation of expression of these cell cycle regulators is relevant to cancer biology 
because their expression has been dysregulated in chronic lymphocytic leukemia [111]. Coupling 
of the circadian cycle and cell cycle has been tested experimentally and with mathematical 
modeling [117]. A recently published study demonstrates that colon cancer cells have Bmal1-
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dependent circadian oscillations in sensitivity to irinotecan, based on in vitro experiments and 
mathematical modeling [94]. The molecular clockwork seems to play an important role in the 
regulation of pathways relevant to cancer biology. 
Our studies demonstrate that glioblastoma susceptibility to TMZ is regulated by the 
circadian clock in a murine model of glioblastoma. We demonstrate a rhythm in TMZ sensitivity 
based on the timing of treatment in vitro. Greatest sensitivity to TMZ occurs at the peak of 
Bmal1 expression.  Through CRISPR-Cas9-mediated disruption of Arntl, we have demonstrated 
an important role for Bmal1 in maintaining rhythmic expression if circadian clock genes and 
rhythmic response to TMZ in vitro.  
Materials and Methods 
Animals: All animals were used in accordance with established Animal Studies Protocols (no. 
20140098 and 20120174) approved by the Washington University Animal Studies Committee 
and followed National Institutes of Health guidelines. Male NCR nude mice used for flank 
implantations were purchased from Taconic Farms, Inc (NY, USA). Founder 
Nf1flox/flox;GFAP-Cre mice were provided by Dr. David Gutmann (Washington University, St. 
Louis, MO) and were housed in the Animal Facilities at Washington University’s School of 
Medicine and Danforth Campus.  
 
Male Astrocyte Cultures: Primary cultures of astrocytes were prepared from individual postnatal 
day 1 Nf1flox/flox;GFAP-Cre mice as previously described [118]. Sex of each mouse was 
determined from tail DNA by PCR for JARID 1C as previously described [119].  All cells from a 
single litter with the same Neurofibromin 1 (Nf1) genotype were pooled based on sex and 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with F12 and 10% 
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fetal bovine serum (FBS). Replicate experiments were performed using astrocytes isolated from 
at least three independent litters. Only male astrocytes were used for these experiments.  
  
Expression of DNp53: A dominant negative P53-encoding retrovirus (DNp53-IRES-eGFP) [120] 
was generated by transfecting Plat-E cells with a pMIG-DNp53-eGFP construct. Media 
containing retrovirus was harvested 48-72 hours post-transfection and stored at -80⁰C until use. 
The resultant viral media was used to infect male Nf1-/- astrocytes with polybrene (5µg/ml, 
Millipore, Billerica, MA). Nf1-/-;DNp53-eGFP positive cells were sorted to purity using a 
MoFlo high speed flow cytometer (Beckman Coulter, Fort Collins), as previously described 
[119].  Results are reported from Mes-GBM astrocytes that were used for up to 8 passages 
following GFP-positive selection by flow cytometry. 
 
Expression of CRISPR-Cas9  expression vectors: Six guide RNAs targeting the Bmal1 (Arntl) 
locus were designed and cloned by the Genome Engineering Center at Washington University in 
St. Louis. Lentiviruses were generated by transfecting 293T HEK cells with the LentiCRISPRv2-
Cas9, delta8.9 and VSV-G plasmids. Media containing CRISPR-Cas9 lentivirus was harvested 
48 hours after transfection and stored at -80⁰C until use. The resultant viral media was used to 
infect Mes-GBM astrocytes with polybrene (5µg/ml, Millipore, Billerica, MA). Mes-GBM 
astrocytes were infected with 6 pooled CRISPR-Cas9 lentiviruses, each containing a unique 
Arntl-targeting guide RNA (Bmal1 CRISPR) or an equivalent titer of CRISPR-Cas9 lacking a 
guide RNA sequence (Control CRISPR). After infection, Nf1-/-;DNp53-Cas9 astrocytes were 
selected with puromycin (2µg/ml, Fisher Scientific, Pittsburgh, PA) for 3 weeks. Clonal lines 
were derived by serial dilution and expansion of single clones. Bmal1 deletion was confirmed by 
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Western Blot (1:500, Novus Biologicals, Littleton, CO). Results are reported from CRISPR-Cas9 
clonal lines used up to 17 passages. 
 
Expression of Per2::dLuc and Bmal1::dLuc reporters: We performed lentiviral infections of 
pure astrocyte cultures using lentiviral reporter constructs expressing firefly luciferase driven by 
the mouse Bmal1 or (Bmal1::dLuc) [89, 90] or Period2 (Per2::dLuc) [59] promoters. Astrocytes 
were incubated with the viral particles for 48 h and then reporter-expressing cells were selected 
based on blasticidin resistance. Media was supplemented with Blasticidin S HCl for 7 days (4 
ug/mL, TOKU-E, Bellingham, WA).  
 
Expression of Caspase-luc reporter: We transfected Mes-GBM astrocyte cultures with the 
Caspase-3/7-luciferase plasmid (Casp-luc; generous gift of Dr. Alnawaz Rehemtulla (University 
of Michigan, Ann Arbor, MI) [121] using Fugene 6 (Promega, Madison, WI). Stable lines were 
selected with 400 ug/ml geneticin (G418; Santa Cruz Biotechnology, Dallas ,TX) and maintained 
in CO2-buffered DMEM supplemented with 10% FBS, 1% penicillin/streptomycin for up to 17 
passages.  
 
Cell Culture: The primary Mes-GBM mouse astrocyte cultures (Nf1-/-;DNp53-eGFP) were 
maintained at 37oC at 5% CO2 in CO2-buffered DMEM supplemented with 10% FBS (Gibco/Life 
Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco/Life Technologies, 
Carlsbad, CA). During bioluminescence recordings, lids were sealed with vacuum grease and 
cell cultures were maintained in HEPES-buffered DMEM supplemented with 10% FBS, B27 
(1X; Gibco/Life Technologies, Carlsbad, CA), as previously reported [86]. All bioluminescent 
[65] 
 
cultures were maintained at 34oC, with the exception of temperature shifts used to entrain 
cultures. Temperature shifts between 30C and 34C occurred every 12 hours across 48 hours prior 
to the start of treatment of the caspase-luciferase reporter dishes. In separate incubators, 
temperatures were shifted in opposite directions to entrain cultures to different phases of 
circadian clock gene expression.  
Subcutaneous implantations: Nf1-/-;DNp53 astrocytes were treated with human epidermal 
growth factor (EGF) (Sigma, St. Louis, MO) for 48 hours prior to implantation into the flanks of 
nude mice. To mobilize and support cell growth in flank implantations, matrigel (100 µL/side 
flank, BD Bioscience) was added to the cells prior to injection. Flank tumors were measured 
weekly with a digital caliper.   
 
Temozolomide treatment of mice: Mice bearing Mes-GBM flank tumors expressing Cas9-only 
(Bmal1 WT) or Bmal1/Arntl-targeting gRNA-Cas9 (Bmal1 KO) were treated with 21 mg/kg/day 
temozolomide (TMZ, Sigma, St. Louis, MO) by oral gavage at 12pm or 12am for 5 consecutive 
days. Vehicle control mice received oral gavage of DMSO diluted in water at 12 am or 12 pm. 
  
Real-time qPCR: All real-time qPCR assays were performed with iTaq™ Universal 
SYBR® Green Supermix (Biorad, Hercules, CA). cDNA was generated from total RNA with 
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) per manufacturer’s instructions. 
PCR and data collection were done using the BioRad CFX Connect Real-Time PCR machine 
and Opticon Monitor 3 Software (Biorad, Hercules, CA). Relative transcript copy number for 
each gene and corresponding GAPDH sample were calculated using the delta-delta-C(q) method 
[122]. 
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Nuclear and histone extractions: Cells in culture were scraped off dishes in PBS and pelleted at 
12,000xg for 15 minutes. The pellet was resuspended in Triton extraction buffer (TEB) (PBS, 
0.5% Triton X-100, 0.02% Sodium Azide, protease (Complete, 1:50, Roche, Basel, Switzerland) 
& phosphatase inhibitor cocktails (II, 1:100; IV, 1:50, Calbiochem, Billerica, MA) and incubated 
for ten minutes at 4C. Lysates from cells or tissue homogenate was pelleted at 2,000 x g for 10 
minutes and pellets were resuspended in hydrochloric acid (HCl) (0.2M), rotating overnight at 
4C. Precipitate was pelleted at 2,000 x g for 10 minutes and supernatant containing histones was 
used for Westerns. Histone protein concentration was assessed by Bradford protein assay prior to 
loading SDS-PAGE gels with histone extracts.   
 
Western blot: Western blots were performed and imaged using the Odyssey Infrared Imaging 
system (LI-COR, Lincoln, NE) as previously described (45). Total protein (30~50 µg per lane) 
was loaded onto a 4% to 12% Nu-Page gradient gel (Invitrogen). Primary antibodies were 
incubated at 4°C overnight. Secondary antibody incubation was at room temperature for 1 hour. 
Primary antibodies used in this study were phospho-S139 H2AX (Molecular Probes, 1:1000), 
H2AX (CST, Danvers, MA, 1:1000), Caspase 3 (CST, Danvers, MA, 1:1000), Cleaved Caspase 
3 (Asp175) (CST, Danvers, MA,1:800), Mouse anti- ß-actin (1:30,000, Sigma); IRdye680 or 800 
conjugated donkey anti-mouse or rabbit IgG (1: 40,000), LI-COR). 
 
Phospho-H2AX immunofluorescence staining and quantification: Mes-GBM astrocytes plated on 
poly-d-lysine-coated glass coverslips were fixed with 4% paraformaldehyde, washed, 
permeabilized with Triton-X-100, incubated with phospho-S139 H2AX primary antibody 
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(Molecular Probes) for 3 hours at 37C, washed with 1x PBS, incubated with Alexa fluor 568 
Donkey α mouse IgG (Life Technologies, Carlsbad, CA) for 1 hour at RT. Then, stained with 
DAPI (Life Technologies, Carlsbad, CA) and mounted on glass slides with Immu-mount 
(Thermo Scientific, Pittsburgh, PA). Nuclear staining intensity was quantified by two individuals 
blinded to treatment conditions using an ImageJ plugin. Staining was quantified across 5 high 
powered fields of view per coverslip and averaged across two coverslips per treatment condition. 
The threshold for positive staining was set after the completion of staining quantification using a 
histogram of a TMZ-treated versus DMSO-treated.  
Bioluminescence recordings in vitro: Light from clock-gene reporters (Bmal1::dLuc or 
Per2::dLuc) was detected in customized light-tight incubators (34°C) equipped with 
photomultiplier tubes (HC135--11; Hamamatsu Corp.) [86-88]. Bioluminescence was integrated 
every 6 min over 4 –7 d after culture medium was exchanged with HEPES-buffered DMEM 
supplemented with B27 (Life Technologies, Carlsbad, CA) and 0.1 mM D-luciferin (Xenogen, 
Alameda, CA). 
 
Bioluminescence recordings in vivo: Adult NCR nude male mice bearing subcutaneous flank 
mes-GBM xenografts were synchronized to a 12-h light/12-h dark cycle for at least 2 weeks 
(lights on from 7:00 A.M. to 7:00 P.M. (LD)). On the first day of imaging, each mouse was 
anesthetized with isoflurane (2% vaporized in O2) at 10:00 A.M., injected i.p. with d-luciferin 
(150 ug/g body weight; Biosynth, Itasca, IL) One minute exposures were captured 10 minutes 
after injection. Every 4 h, the mice were reanesthetized with isoflurane and imaged with an ultra-
sensitive CCD camera in a light tight box (Stanford Photonics; bin factor, 2; 1/f stop; open filter; 
Stanford Photonics, Palo Alto, CA). Mice received subcutaneous saline for hydration (0.5 cc 
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every 8 hours), were returned to their cages, and awoke within 3 min after removal of the 
anesthetic. This procedure was repeated every 4 h for 48 h, during which time the mice showed 
no adverse effects of repeated 20-min anesthesia.  
Statistical Analysis: Standard statistical analyses were completed with GraphPad Prism version 
6.0 (GraphPad, San Diego, CA). Circadian period of bioluminescence recordings were analyzed 
with Chronostar V2.0 software. 
Results 
Clock genes are genetically altered in human gliomas 
The epidemiologic evidence supporting a link between the circadian clock and cancer is 
strengthened by the deregulation of expression of core circadian clock genes in a variety of 
cancer types [108, 109]. To compare the frequency of genetic alterations in core clock genes 
across cancers, we queried The Cancer Genome Atlas (TCGA) database and identified the 
frequency of amplifications, deletions and mutations in 16 core circadian clock genes (Table 
3.1) across 9 cancer types (Figure 3.1A). Uterine cancer had the highest rate of genetic alteration 
in core clock genes, while acute myeloid leukemia had the lowest rate of the cancers surveyed in 
this analysis. GBM ranked in between these two, with core clock genes are altered in 14.6% of 
GBM patients in a TCGA dataset of 281 GBM patient specimens [123]. The most frequently 
altered genes are listed in Figure 3.1B with the types of genetic alterations listed for each gene 
(Figure 3.1B). Less frequently altered core clock genes are listed in the figure legend. A full list 
of frequency of genetic alteration for each core clock gene can be found in Table 3.1. This 
analysis indicates the presence of copy number alterations and mutations in a variety of cancers 
that alter the molecular clock. 
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Table 3.1. List of Core Circadian Clock Genes 
Clock Gene Symbol Clock Gene Product 
Name 
Role in the Molecular Clock Frequency 
of Genetic 
Alteration 
In GBM 
Arntl BMAL1 Transcription factor; Activate 
transcription of CCGs 
1% 
Clock CLOCK Transcription factor; Activate 
transcription of CCGs 
5% 
Arntl2 BMAL2 Transcription factor; Activate 
transcription of CCGs 
1% 
NPAS2 NPAS2 Transcription factor; Activate 
transcription of CCGs 
0.4% 
Per1 PERIOD1 CCG; negative feedback on 
Clock-Bmal1 dimer 
0.7% 
Per2 PERIOD2 CCG; negative feedback on 
Clock-Bmal1 dimer 
0.7% 
Per3 PERIOD3 CCG; negative feedback on 
Clock-Bmal1 dimer 
2% 
Cry1 CRYPTOCHROME1 CCG; negative feedback on 
Clock-Bmal1 dimer 
0.7% 
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Cry2 CRYPTOCHROME2 CCG; negative feedback on 
Clock-Bmal1 dimer 
0.4% 
CSNK1D CASEIN KINASE 1 
delta 
Phosphorylate Period proteins 0.4% 
CSNK1E CASEIN KINASE 1 
epsilon 
Phosphorylate Period proteins 0.4% 
RORA Retinoid-related orphan 
receptor alpha 
Activate Bmal1 transcription 0.7% 
RORB Retinoid-related orphan 
receptor beta 
Activate Bmal1 transcription 2% 
RORC Retinoid-related orphan 
receptor gamma 
Activate Bmal1 transcription 0.4% 
Nr1d1 REV-ERB alpha Repress Bmal1 transcription 0.4% 
Nr1d2 REV-ERB beta Repress Bmal1 transcription 0% 
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Figure 3.1. Frequency of genetic alterations in core clock genes in cancer. A) Comparison 
of frequency of genetic alterations in core clock genes (full list of genes in Table 3.1) in different 
types of cancer using data from The Cancer Genome Atlas (TCGA). Types of genetic alterations 
are color coded: amplifications (red), deletions (blue), mutations (green) or tumors with multiple 
alterations (gray). Cancer type (Total % Frequency, [Ref]): Uterine corpus endometroid 
carcinoma (31.3%,[124]), Metastatic prostate cancer (30.7%, [125]), Ovarian serous 
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cystadenocarcinoma (28.5%, [126]), Lung squamous cell carcinoma (27.5%, [127]), breast 
invasive carcinoma (26.1%, [128]), colorectal adenocarcinoma (16%, [129]), glioblastoma 
(14.6%, [123]), renal clear cell carcinoma (9.1%, [130]), acute myeloid leukemia (3.7%, [131]). 
B) Frequency and identity of genetic alterations in clock genes in a dataset from 281 GBM 
patients [123]. Core clock genes with greatest alteration frequency are listed in the figure. The 
following core clock genes had low rates of genetic alteration: NPAS2 (0.4%), CRY1 (0.7%), 
CRY2 (0.4%), PER1 (0.7%), PER2 (0.7%), CSNK1D (0.4%), CSNK1E (0.4%), RORA (0.7%), 
RORC (0.4%), NR1D1 (0.4%). 
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Circadian oscillations in clock gene expression in Mes-GBM astrocytes 
In order to investigate the circadian biology of GBM, we utilize a mesenchymal GBM 
murine astrocyte model (Mes-GBM) that has been previously used and characterized by our lab 
[119]. The Mes-GBM mouse astrocytes have lost Neurofibromin 1 (Nf1) expression and express 
a dominant-negative p53 construct [120] to mimic deletion/mutation of Nf1 and p53, two genetic 
alterations commonly found in mesenchymal GBM [16]. Due to the known sexual dimorphism 
in mesenchymal GBM and previous research demonstrating greater benefit of chronotherapy in 
male patients with metastatic colorectal cancer [132], we limited our studies to male mes-GBM 
astrocytes. To characterize gene expression rhythms in the male mes-GBM astrocytes, we 
transduced the cells to express a luciferase reporters of gene expression for Period2 (Per2-luc) or 
Bmal1 (Bmal1-luc) [59, 89, 90]. To characterize these rhythms as circadian, we calculated the 
period of circadian oscillation across 4-7 days of recording. Male mes-GBM astrocytes showed 
oscillations in Per2-luc and Bmal1-luc expression (Figure 3.2A) with periods of 22.2 h and 25.3 
h, respectively, in these examples. On average, the periods of Per2-luc and Bmal1-luc 
oscillations are 23.0 h and 23.6 h, respectively (please see Table 3.2 for details). Previous studies 
have shown that Bmal1 transcription oscillates in anti-phase to clock-controlled genes (CCGs), 
reaching peak expression levels at the nadir of CCG expression levels [104]. To examine the 
phase relationship between Per2 and Bmal1 expression in the Mes-GBM astrocytes, we 
calculated the average length of time between Bmal1 peak and Per2 peak across paired cultures 
plated and recorded simultaneously. This analysis revealed an average gap of 8.8 h between the 
peaks of Per2 and Bmal1 expression on Day 2 of recording (see Table 3.2). This demonstrates 
that most, but not all, paired Bmal1-luc and Per2-luc cultures reach their peaks at opposite times 
of day. This fairly reliable anti-phase oscillation of Bmal1 and Per2 reporters demonstrates that 
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the transcription-translation feedback loop, and the stabilizing loop of Bmal1 expression are 
intact in the Mes-GBM astrocytes with slight variations between platings. Due to this minor 
variability, TMZ chronotherapy experiments was performed with a reporter dish recording 
bioluminescent rhythms of Per2-luc and/or Bmal1-luc to measure the exact phase of gene 
expression for the plating of each individual experiment. Based on these data, we conclude that 
Mes-GBM astrocytes have an intact molecular clock with a period of oscillation near 24 h. 
Table 3.2. Summary of Per2-luc and Bmal1-luc traces in Mes-GBM astrocytes in vitro. 
Circadian characterization of clock gene reporters Mean ± SEM N 
Period of Per2-luc bioluminescence  23.0 ± 0.7 h 16 
Period of Bmal1-luc bioluminescence 23.6 ± 0.4 h 22 
Period of clock gene expression (Per2-luc and Bmal1-luc) 23.3 ± 0.4 h 38 
Time between peaks in Per2-luc and Bmal1-luc expression on 
Day 2 
8.8 ± 2.1 h 4 (Pairs) 
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Figure 3.2. Mes-GBM astrocytes have rhythmic sensitivity to temozolomide in vitro. A) 
Mes-GBM astrocytes express luciferase reporters of Bmal1 (black) and Per2 (gray) in anti-
phase, with rhythmic periods of 25.3 h and 22.2 h, respectively, in these representative traces. B) 
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Bmal1::dLuciferase reporter dish showed oscillation of bioluminescence over time (one 
representative trace, N=3). Arrows indicate times of TMZ or DMSO treatment (hours after 
plating). C) TMZ-induced growth inhibition varies with time of treatment (one representative 
experiment, N =3).  
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Circadian rhythms in Temozolomide-induced growth inhibition in vitro 
To determine whether the circadian oscillations in clock gene expression rendered the 
Mes-GBM astrocytes differentially sensitive to TMZ when treated at different phases of Bmal1-
luc expression, we treated cells with 1 mM TMZ or vehicle (DMSO) at 1 of 4 time points for 6 
hours from 24 to 42 hours post-plating (Figure 3.2B, arrows). Trypan blue-stained cells were 
counted 72 hours after the addition of TMZ or vehicle. Growth inhibition for each time point was 
calculated as the number of TMZ-treated living cells divided by the number of DMSO-treated 
living cells. This fraction was expressed as a percentage, with 100% growth inhibition equivalent 
to the death of all TMZ-treated cells. The greatest TMZ-induced inhibition of growth occurred 
near the peak of Bmal1-luc expression (Figure 3.2C).  The results shown in Figure 2 are from 
one representative experiment. The correlation between greatest growth inhibition and Bmal1 
peak occurred in two additional experiments, using two independently derived lots of Mes-GBM 
astrocytes (data not shown). Thus, TMZ sensitivity of Mes-GBM astrocytes varies with the 
phase of Bmal1 expression.  
Circadian rhythms in DNA damage response 
To assess whether the time-dependent oscillations in growth inhibition are due to rhythms 
in response to TMZ-induced DNA damage, we treated mes-GBM astrocytes with 1mM TMZ or 
vehicle (DMSO) at 4 different times of day and stained for phosphorylation of histone H2AX, a 
commonly used marker for DNA double strand breaks [91] and an early step in the DNA damage 
response pathway [133]. Each dish was exposed to TMZ or vehicle for 6 hours, media was 
changed and cells were fixed 18 hours after the addition of TMZ or vehicle. Nuclear staining for 
phospho-H2AX (p-Ser139) was quantified by ImageJ analysis of integrated density of 
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fluorescent images. We set a threshold for positive staining and counted the number of phospho-
H2AX positive cells per sample. Representative images of fluorescence staining for each 
treatment group are shown in Figure 3A. Phospho-H2AX-positive cells were quantified as a 
percentage of total DAPI-stained nuclei per field of view (Figure 3.3C). Greatest 
phosphorylation of H2AX occurred near the peak of Bmal1-luc expression in the reporter dish 
(Figure 3.3B). We quantified the increase in the percent of phospho-H2AX-positive staining by 
normalizing to Mes-GBM astrocytes treated with DMSO at the trough of Bmal1-luc expression 
(Figure 3.3D). The mean difference between TMZ- and DMSO-induced phosphorylation of 
H2AX was statistically significant at the peak of Bmal1-luc expression, not the trough (Two-way 
ANOVA, Tukey’s multiple comparisons, p < 0.05, n = 3). There was a 2.8-fold difference in the 
average TMZ response at the peak versus trough of Bmal1-luc expression. These results 
demonstrate a time of day-dependent rhythm in the response of Mes-GBM astrocytes to TMZ-
induced DNA double strand breaks. 
 
 
 
 
 
 
 
[79] 
 
 
 
Figure 3.3. Phosphorylation of histone H2AX varies with time of treatment in vitro. A) 
Representative nuclear staining of DNA (blue, DAPI) and phospho-H2AX (red) near the peak 
and trough of Bmal1::dLuc bioluminescence. B) Percent of cells positive for nuclear phospho-
H2AX staining varies with time of TMZ or DMSO treatment (one representative experiment, N 
=3). C) Bmal1::dLuc reporter dish showed oscillation of bioluminescence over time (one 
representative experiment, N =3).D) Fold change in percent phospho-H2AX staining relative to 
DMSO-treated Mes-GBM astrocytes treated at the trough of Bmal1 expression.  
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Circadian rhythms in TMZ-induced activation of apoptosis 
The growth inhibition studies demonstrated a rhythm in TMZ sensitivity based on cell 
counting. The number of cells in a culture after treatment is the sum of cell proliferation and cell 
death. This rhythm in cell number combined with the rhythm we have identified in H2AX 
phosphorylation led us to test whether there was a time of day-dependent rhythm in TMZ-
induced apoptosis. To test whether TMZ-induced apoptosis changes with time of day of 
treatment, we quantified the activation of apoptosis with a luciferase reporter of caspase 3 and 7 
activity [121]. We treated Mes-GBM astrocytes stably expressing the caspase reporter with TMZ 
or DMSO for 6 hours at four different phases of Per2-luc expression (Figure 3.4A) and tracked 
bioluminescence after treatment. To quantify the TMZ-induced activation of the caspase 
reporter, the DMSO-induced bioluminescence was subtracted from the TMZ-induced 
bioluminescence at each time point. We quantified the bioluminescence in each culture 48 hours 
after the addition of TMZ and expressed the caspase reporter activation as fold change relative to 
treatment at the falling phase of Per2-luc in the Bmal1 WT reporter dish (Figure 3.4B). There 
was a statistically significant increase in caspase-luc bioluminescence when Mes-GBM 
astrocytes were treated at the trough of Per2 (Dunn’s multiple comparisons test, p<0.05). Thus, 
the Mes-GBM astrocytes have a circadian rhythm in TMZ-induced activation of apoptosis. 
CRISPR-Cas9-mediated disruption of Bmal1 led to loss of rhythmic Per2 expression 
The correlation between high Bmal1 expression and high TMZ sensitivity led us to 
hypothesize that increased TMZ sensitivity is Bmal1-dependent. We used the CRISPR-Cas9 
system to target and disrupt Arntl, the gene encoding BMAL1. This disruption led to loss of 
BMAL1 protein expression (data not shown). Loss of Bmal1 disrupted circadian rhythms in 
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Per2-luc expression (Figure 3.4C). These data demonstrate disrupted regulation of the 
molecular clock in Bmal1 KO Mes-GBM astrocytes.  
Circadian rhythms in activation of apoptosis are Bmal1-dependent 
To determine the necessity of Bmal1 expression to generate rhythms in TMZ-induced 
apoptosis, Bmal1 knockout Mes-GBM astrocytes stably expressing the caspase reporter were 
treated at four different times according to the Per2-luc rhythm of a Bmal1 WT culture (Figure 
3.4A). CRISPR-mediated loss of Bmal1 expression abolished the rhythm in TMZ-induced 
caspase activity (Figure 3.4D). There is no statistically significant difference in caspase reporter 
induction across treatment times (One-way ANOVA, Dunn’s multiple comparisons test, p> 
0.05). The loss of rhythmic activation of TMZ-induced apoptosis in the Bmal1 KO Mes-GBM 
astrocytes demonstrates a disruption of the circadian regulation of sensitivity to TMZ. 
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Figure 3.4. Rhythmic Per2::dLuc expression and activation of apoptosis are Bmal1-
dependent in vitro. A) Mes-GBM astrocytes expressed Per2::dLuc rhythmically, with a period 
of 22.2 h. B) CRISPR-mediated loss of Bmal1 was associated with arrhythmic expression of 
Per2::dLuc. C) Temozolomide-induced activation of the bioluminescent caspase reporter created 
a time of day –dependent change in bioluminescence in Bmal1 WT, with the highest caspase 
activation at the trough of Per2 (peak of Bmal1) (One-way ANOVA, Dunn’s multiple 
comparisons test, p<0.05). D) There was no statistically significant change in caspase reporter 
activation in Bmal1 KO Mes-GBM astrocytes over time. (One-way ANOVA, Dunn’s multiple 
comparisons test, p> 0.05) 
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Discussion 
Our study uniquely demonstrates a tumor cell-intrinsic time of day-dependent variation in 
response to TMZ-induced DNA damage in glioblastoma. We employed a variety of methods to 
assess tumor response to TMZ treatment: measurements of DNA repair, apoptosis and overall 
growth inhibition. We demonstrated a daily rhythm in DNA repair by demonstrating a rhythm in 
histone H2AX phosphorylation. We have also demonstrated a circadian rhythm in the activation 
of apoptosis using a bioluminescent reporter of effector caspase activity. These rhythms in DNA 
repair and apoptosis correlate well with the rhythm we observed in growth inhibition following 
treatment with TMZ at different times of day. Taken together, these data support a rhythm in 
tumor response to TMZ that exists at the level of DNA repair and leads to a rhythm in 
programmed cell death. 
These experiments build upon research that has previously demonstrated regulation of the 
DNA damage response by the circadian clock. Direct protein-protein interactions of PER1 and 
PER3 with ATM and Chk2 enhanced Chk2 phosphorylation and activation of cell cycle arrest in 
response to DNA double strand breaks [70, 71]. CRY1 and TIMELESS modulate Chk1 
phosphorylation in a similar manner [74-76]. All of these studies utilized overexpression vectors 
or RNAi-mediated knockdown to study their influence on DNA damage response. In contrast, 
our studies assess circadian modulation of the cellular response to DNA damage without 
knocking down or overexpressing any components of the clock, providing insight into the daily 
fold-change in sensitivity we see based on endogenous rhythms. Future studies should 
characterize endogenous rhythms in sensitivity to chemotherapy in a variety of cancer cell types 
to determine whether our studies demonstrate cell-intrinsic rhythms in chemotherapy sensitivity 
that are unique to GBM. 
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 Timing of chemotherapy administration to biological rhythms like DNA damage 
response can alter the clinical outcomes of chemotherapy treatments in cancer patients. Cancer 
treatments with several DNA damaging agents have been improved through chronotherapy. 
Chronomodulated delivery of oxaliplatin with peak delivery at 0400 h combined with 5-
fluorouracil and leucovorin delivered overnight reduced mucositis to allow patients to stay on 
higher chemotherapy doses for a longer time. Thus, improving tumor response to treatment (Levi 
1994). Treatment of advanced ovarian cancer with doxorubicin in the morning and cisplatin in 
the evening reduced bone marrow toxicity, thereby causing fewer dose reductions and treatment 
delays [36]. In both of these applications of chronotherapy effectively reduced toxicity. 
 There was a consistent correlation between the peak of Bmal1 expression and the greatest 
sensitivity to TMZ. Growth inhibition was maximal at the peak of Bmal1 expression. The 
greatest number of TMZ-treated cells were phospho-H2AX positive 18 hours after treatment 
near the peak of Bmal1. This level of phosphorylation is the net result of DNA damage 
(phosphorylation of H2AX by ATM) and resolution of DNA damage (dephosphorylation as 
DNA is repaired). Eighteen hours after exposure to TMZ, the phosphorylation state of H2AX 
likely corresponds to the kinetics of DNA repair more than sensing of DNA damage. Therefore, 
the high phosphorylation state of H2AX at the peak of Bmal1 expression corresponds to slower 
kinetics of repair. The activation of apoptosis, as reported by the caspase-3/7 bioluminescent 
reporter, was greatest at the trough of Per2-luc expression. Consistent with canonical regulation 
of the molecular clock, Mes-GBM astrocytes have antiphase oscillations of Bmal1-luc and Per2-
luc in vitro. Therefore, we can conclude that greatest activation of apoptosis occurs at the peak of 
Bmal1. At every level of response to TMZ that has been tested in the Mes-GBM astrocytes, there 
has been a correlation between high Bmal1 expression and reduced ability for the tumor cell to 
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survive TMZ-induced DNA damage. These findings are consistent with daily variations in colon 
cancer cell sensitivity to irinotecan. Dulong and colleagues have described a correlation between 
peak Bmal1 expression and greatest irinotecan-induced cytotoxicity in vitro [94]. Irinotecan and 
TMZ both cause DNA damage and induce the greatest cytotoxicity at the peak of Bmal1, 
suggesting circadian regulation of a common DNA repair pathway in response to both of these 
chemotherapies. 
 The correlation between the peak of Bmal1 expression and the greatest sensitivity to 
TMZ combined with the loss of circadian rhythm in TMZ-induced apoptosis in Bmal1 KO Mes-
GBM astrocytes suggests an important role for BMAL1 in regulating response to DNA damage. 
Overexpression of Bmal1 increases sensitivity of colon cancer cells to oxaliplatin [69]. Bmal1 
knockdown reduced etoposide-induced apoptosis of colon cancer cells [68].  These data are 
consistent with our findings that loss of Bmal1 leads to ablation of the high level of caspase 
activation correlated to the trough of Per2-luc expression in rhythmic tumor cells. There are no 
data showing a direct interaction of BMAL1 with proteins involved in apoptosis, but there are 
reports of Per2 overexpression altering expression of apoptotic genes [81]. These findings 
suggest that one or more clock-controlled gene products mediate the daily oscillations in 
activation of apoptosis following DNA damage.   
Based on Bmal1 knockout studies performed in other cell types [60, 64], we predicted 
that loss of Bmal1 would lead to loss of daily oscillations in Per2-luc expression in vitro. We 
have demonstrated rhythmic expression of the Per2-luc bioluminescent reporter in cultured cells. 
Loss of Bmal1 leads to arrhythmic expression of Per2-luc in vitro. We use the Per2-luc reporter 
as a way to detect and measure oscillations in clock-controlled genes (CCGs). The loss of rhythm 
in TMZ sensitivity in the Bmal1 KO Mes-GBM astrocytes provides a functional output 
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supporting the hypothesis that rhythmic clock gene expression is required for regulation of 
response to TMZ. Currently, the mechanism underlying circadian regulation of TMZ sensitivity 
is unknown. However, future studies of CCGs related to DNA damage response and apoptosis 
may help identify the key regulators of this rhythmic sensitivity. Identifying rhythmic transcripts 
of DDR- and apoptosis-related genes that lose rhythmicity in Bmal1 KO cells would provide a 
list of candidate regulators. At present, the Bmal1-luc and Per2-luc reporters serve as useful tools 
to help us understand the regulation of the circadian clock within tumor cells and to guide the 
search for the mechanism of circadian regulation of the tumor cell-intrinsic response to TMZ.   
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Chapter 4: Circadian clock gene expression and TMZ chronotherapy of 
glioblastoma models in vivo 
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Abstract 
A series of in vivo GBM mouse studies have been performed to test whether the 
observations we made about circadian regulation of gene expression and TMZ sensitivity in vitro 
will persist in vivo. Using a human glioblastoma cell line (U87) and a murine model on the 
mesenchymal subtype of GBM (Nf1-/-;DNp53), we identified daily rhythms in clock gene and 
clock-controlled gene expression in vivo. We have demonstrated Bmal1-dependence of this 
rhythm in our murine GBM model in vivo. In our in vivo chronotherapy trials, we timed the 
delivery of TMZ to the in vivo rhythms we measured. The U87 xenograft chronotherapy trials 
yielded inconsistent tumor growth and TMZ-induced growth inhibition. None of these U87 
xenograft chronotherapy trials revealed a time of day-dependent difference in overall survival. 
Bmal1 KO Mes-GBM flank tumors showed no difference in acute or long-term TMZ treatment 
outcomes based on timing of TMZ administration. Together these data are insufficient to support 
the translation of our in vitro data to a pre-clinical model of TMZ chronotherapy for GBM. 
However, the variable and unexpected outcomes of these in vivo chronotherapy trials provide 
valuable information that will guide the design of future studies.  
Introduction 
Glioblastoma, a WHO grade IV astrocytoma, is the most common and aggressive 
malignant primary brain tumor in adults. Despite decades of research and countless clinical 
trials, median survival is still only approximately 15 months. Therefore, all opportunities to 
improve upon the current treatment outcomes should be pursued. 
For many years, surgical resection and radiation therapy were the standard of care. In 
2005, a landmark paper published in the New England Journal of Medicine demonstrated an 
increase in progression-free and overall survival with the addition of temozolomide (TMZ) 
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chemotherapy [21]. Since then, clinicians have tried a variety of TMZ treatment schedules, but 
none of them have taken into account the time of day of TMZ administration. As an oral 
medication, it is easy to regulate the timing of treatment. TMZ has a blood plasma half-life of 1.8 
h [101], in addition to a short half-life (1.7-2.6 h) within tumors in animal models of GBM [102, 
103], making it an ideal candidate for chronotherapy.  
Oncologists have tested the efficacy and tolerability of chemotherapeutic agents at 
different times of day in a variety of cancer types. The administration of medications based on 
daily rhythms in biological processes is known as chronotherapy. Chronotherapy has increased 
5-year survival rates in acute lymphoblastic leukemia and ovarian cancer patients, and increased 
the objective response rate in colorectal cancer while simultaneously reducing toxicities [30, 35, 
36]. Despite successful therapeutic outcomes, chronotherapy has never been applied to the 
treatment of brain tumors. 
Our daily rhythms in sleep, hormone release, and many other physiological processes are 
driven by an internal clock [54]. A molecular clocks exist within most cells to keep time at the 
cellular level. The core molecular clock consists of two transcription factors, Bmal1 and Clock, 
which activate transcription of downstream genes. The genes activated by the Bmal1-Clock 
transcription dimer are known as clock-controlled genes (CCGs). Among those CCGs, the gene 
products of the Period family (Per1, Per2, Per3), and the Cryptochrome family (Cry1 and Cry2) 
provide negative feedback to block further transcriptional activation by the Bmal1-Clock dimer 
[104]. This feedback loop creates circadian oscillations in clock-controlled gene expression. A 
stabilizing feedback loop regulates transcription of the Bmal1 gene (Arntl), creating an 
oscillation in Arntl expression that is anti-phase to the clock-controlled genes [105-107]. Loss of 
Arntl leads to loss of rhythms in individual cells [60, 64], and rest-activity rhythms [60], 
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demonstrating the crucial role Bmal1 plays in regulating circadian function. Our studies take 
advantage of that weakness in the clock to explore the contributions of the circadian clock to the 
response of glioblastoma to TMZ. 
Many links have been made between circadian clocks and cancer in humans and mice. 
Epidemiological studies have demonstrated that shift workers have a higher risk of developing 
cancer [47, 108], creating a correlation between disrupted clocks and tumorigenesis in humans. 
To build on this shift work-cancer link, scientists have recently demonstrated an increased risk of 
breast cancer development in female mice exposed to a chronically shifting light schedule [40]. 
Circadian rhythms in human physiology have also been linked to survival for colorectal and 
breast cancer patients [84]. These studies provide correlations between circadian rhythms and 
cancer, but do not prove that disruption of circadian rhythms cause cancer. 
A rapidly growing field of research has demonstrated molecular ties between the 
circadian clock and cancer-relevant pathways. Expression of circadian clock genes has been 
deregulated in a variety of cancer types, including gliomas [109, 111, 113]. At the molecular 
level, circadian clock proteins have been directly linked to DNA damage response. Localization 
of CLOCK proteins at sites of H2AX phosphorylation demonstrate a recruitment of CLOCK to 
sites of DNA damage, but do not establish a role for CLOCK at those sites. The circadian role of 
mammalian Timeless (Tim) remains unknown, but requirement of Tim for DNA damage 
checkpoint responses has been demonstrated through interactions with the ATR-Chk1, and 
ATM-Chk2 pathways [74, 77, 114-116]. PER1 protein interacts directly with ATM and Chk2, 
enhancing activation of the checkpoint pathway [70]. PER3 also interacts with and enhances 
ATM-mediated phosphorylation of Chk2 [71]. Rhythmic expression of the base excision repair 
protein, XPA, creates daily rhythms in UV-induced DNA damage [78]. Circadian rhythms in 
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transcription have been demonstrated for cell cycle regulators Wee1, c-Myc and CyclinD1 [67, 
80]. Deregulated expression of circadian and these three cell cycle regulators has been 
demonstrated in chronic lymphocytic leukemia [111]. Coupling of the circadian cycle and cell 
cycle has been tested experimentally and with mathematical modeling [117]. This field of study 
has provided many examples of regulation of DNA damage response, cell cycle and apoptosis by 
the molecular clock. These studies outline a role for the molecular clock in regulating cellular 
processes that often become aberrant in the setting of cancer, characterizing clock proteins as 
tumor suppressors.  
Many rodent chronotherapy studies have demonstrated improved outcomes for a variety 
of tumor models. Mouse models of leukemia and mammary adenocarcinoma had greater survival 
rates following treatment with doxorubicin during the day time compared to night [134, 135]. 
Sarcoma-bearing rats had greater tumor growth inhibition when treated with doxorubicin in the 
middle of the night compared to the early daylight hours [136]. Osteosarcoma-bearing mice had 
greater tumor growth inhibition and median survival when treated with oxaliplatin during the 
early night compared to mid-day [135]. However, two cisplatin-based chronotherapy studies in 
rats with plasmacytoma and mice with pancreatic adenocarcinoma showed no changes in anti-
tumor efficacy with timing of chemotherapy administration [135]. Chronotherapy may not 
always provide improved outcomes, but there are many examples of success using a variety of 
chemotherepaeutics in several different rodent models of cancer.  
Our study seeks to understand the circadian regulation of susceptibility to TMZ in a 
murine model of glioblastoma. We have previously demonstrated rhythms in clock gene 
expression and TMZ sensitivity based on the timing of treatment in vitro. We now test whether 
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the observations we have made in cell culture are maintained in vivo. We have demonstrated an 
important role for Bmal1 in maintaining rhythmic expression if circadian clock genes in vivo. 
However, we have not demonstrated a time of day-dependent sensitivity to TMZ in Bmal1 WT 
U87 xenografts or Bmal1 KO Mes-GBM flank tumors. These experiments teach us valuable 
lessons in experimental design that will help us design future experiments.  
Materials and Methods 
Animals: All animals were used in accordance with established Animal Studies Protocols (no. 
20140098 and 20120174) approved by the Washington University Animal Studies Committee 
and followed National Institutes of Health guidelines. Male NCR nude mice used for flank 
implantations were purchased from Taconic Farms, Inc (NY, USA). Founder 
Nf1flox/flox;GFAP-Cre mice were provided by Dr. David Gutmann (Washington University, St. 
Louis, MO) and were housed in the Animal Facilities at Washington University’s School of 
Medicine and Danforth Campus.  
 
Male Astrocyte Cultures: Primary cultures of astrocytes were prepared from individual postnatal 
day 1 Nf1flox/flox;GFAP-Cre mice as previously described [118]. Sex of each mouse was 
determined from tail DNA by PCR for JARID 1C as previously described [119].  All cells from a 
single litter with the same Neurofibromin 1 (Nf1) genotype were pooled based on sex. Replicate 
experiments were performed using astrocytes isolated from at least three independent litters. 
Only male astrocytes were used for these experiments.  
  
Expression of DNp53: A dominant negative P53-encoding retrovirus (DNp53-IRES-eGFP) [120] 
was generated by transfecting Plat-E cells with a pMIG-DNp53-eGFP construct. Media 
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containing retrovirus was harvested 48-72 hours post-transfection and stored at -80⁰C until use. 
The resultant viral media was used to infect male Nf1-/- astrocytes with polybrene (5µg/ml, 
Millipore, Billerica, MA). Nf1-/-;DNp53-eGFP positive cells were sorted to purity using a 
MoFlo high speed flow cytometer (Beckman Coulter, Fort Collins), as previously 
described[119].  Results are reported from Mes-GBM astrocytes that were used for up to 8 
passages following GFP-positive selection by flow cytometry. 
 
Expression of CRISPR-Cas9 expression vectors: Six guide RNAs targeting the Bmal1 (Arntl) 
locus were designed and cloned by the Genome Engineering Center at Washington University in 
St. Louis. Lentiviruses were generated by transfecting 293T HEK cells with the LentiCRISPRv2-
Cas9, delta8.9 and VSV-G plasmids. Media containing CRISPR-Cas9 lentivirus was harvested 
48 hours after transfection and stored at -80⁰C until use. The resultant viral media was used to 
infect Mes-GBM astrocytes with polybrene (5µg/ml, Millipore, Billerica, MA). Mes-GBM 
astrocytes were infected with CRISPR-Cas9 lentiviruses containing 6 unique Arntl-targeting 
guide RNAs (Bmal1 CRISPR) or an equivalent titer of CRISPR-Cas9 lacking a guide RNA 
sequence (Control CRISPR). After infection, Nf1-/-;DNp53-Cas9 astrocytes were selected with 
puromycin (2µg/ml, Fisher Scientific, Pittsburgh, PA) for 3 weeks. Clonal lines were derived by 
serial dilution and expansion of single clones. Results are reported from CRISPR-Cas9 clonal 
lines used up to 16 passages for subcutaneous implantation. 
 
Expression of Per2::dLuc and Bmal1::dLuc reporters: We performed lentiviral infections of 
pure astrocyte cultures using lentiviral reporter constructs expressing firefly luciferase driven by 
the mouse Bmal1 or (Bmal1::dLuc) [89, 90] or Period2 (Per2::dLuc) [59] promoters. Astrocytes 
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were incubated with the viral particles for 48 h and then reporter-expressing cells were selected 
based on blasticidin resistance. Media was supplemented with Blasticidin S HCl for 7 days (4 
ug/mL, TOKU-E, Bellingham, WA) to select Mes-GBM astrocytes. The U87MG cells were not 
Blasticidin-selected after infection with the Bmal1::dLuc reporter.   
 
Cell Culture: The human U87 glioblastoma cell line was purchased from American Type Culture 
Collection (ATCC). For the chronotherapy experiment, U87 cells were infected with a CMV-
GFP-luciferase (CMV-luc) lentivirus and selected by GFP signal intensity by flow cytometry 
prior to intracranial implantation, as done previously [137, 138]. The murine mesenchymal GBM 
astrocyte model was generated in the lab, as described above. Prior to in vivo implantation, all 
cells were maintained at 37oC at 5% CO2 in CO2-buffered DMEM supplemented with 10% FBS 
(Gibco/Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco/Life 
Technologies, Carlsbad, CA).  
 
Intracranial implantations: Intracranial xenografts were generated as described previously [137, 
138]. Homozygous NCR nude mice (Taconic Farms, Germantown, NY) were anesthetized 
[intraperitoneal ketamine (87 mg/kg)/xylazine (13 mg/kg); Phoenix Pharmaceuticals, 
Burlingame, CA], the cranium was exposed, and a small hole was made 2mm lateral and 
posterior to the bregma with a size 34 inverted cone burr (Dremel, Racine, WI). Mice were 
positioned in a stereotactic frame (Stoelting, Wood Dale, IL) and 50,000 cells in PBS were 
injected through a 27-gauge needle over 2 min at 2.5 mm below the dura mater. The incision was 
closed with Vetbond (3M, St. Paul, MN). 
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Subcutaneous implantations: Nf1-/-;DNp53 astrocytes were treated with human EGF (Sigma, St. 
Louis, MO) for 48 hours prior to implantation into the flanks of nude mice. To mobilize and 
support cell growth in flank implantations, matrigel (100 µL/side flank, BD Bioscience) was 
added to the cells prior to injection. Cohort 1 received 1x106 cells per flank injection. Cohort 2 
received 2x106 cells per flank injection. Flank tumors were measured weekly with a digital 
caliper.   
 
Temozolomide treatment of mice: Mice bearing intracranial U87 xenografts or Mes-GBM flank 
tumors expressing Cas9-only (Bmal1 WT) or Bmal1/Arntl-targeting gRNA-Cas9 (Bmal1 KO) 
were treated with 21 mg/kg/day temozolomide (TMZ, Sigma, St. Louis, MO) by oral gavage for 
5 consecutive days. Vehicle control mice received oral gavage of DMSO diluted in water. 
  
Real-time qPCR: All real-time qPCR assays were performed with iTaq™ Universal 
SYBR® Green Supermix (Biorad, Hercules, CA). cDNA was generated from total RNA with 
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) per manufacturer’s instructions. 
PCR and data collection were done using the BioRad CFX Connect Real-Time PCR machine 
and Opticon Monitor 3 Software (Biorad, Hercules, CA). Relative transcript copy number for 
each gene and corresponding Gapdh sample were calculated using the delta-delta-C(q) method 
[122]. PCR primers used in these studies are listed in Supplemental Table 1. 
 
Nuclear and histone extractions: Extraction from tissue required homogenization in 10mM DTT 
supplemented with PMSF, protease and phosphatase inhibitor cocktails, 30 min incubation on ice 
and 10 seconds of sonication. The pellet was resuspended in TEB (PBS, 0.5% Triton X-100, 
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0.02% Sodium Azide, protease (Complete, 1:50, Roche, Basel, Switzerland) & phosphatase 
inhibitor cocktails (II, 1:100; IV, 1:50, Calbiochem, Billerica, MA) and incubated for ten minutes 
at 4C. Lysates from tissue homogenate was pelleted at 2,000xg for 10 minutes and pellets were 
resuspended in HCl (0.2M for cells, 0.4M for tissue), rotating overnight at 4C. Precipitate was 
pelleted at 2,000 x g for 10 minutes and supernatant containing histones was used for Westerns. 
Histone protein concentration was assessed by Bradford protein assay prior to loading SDS-
PAGE gels with histone extracts.   
 
Western blot: Western blots were performed and imaged using the Odyssey Infrared Imaging 
system (LI-COR, Lincoln, NE) as previously described (45). Total protein (30~50 µg per lane) 
was loaded onto a 4% to 12% Nu-Page gradient gel (Invitrogen). Primary antibodies were 
incubated at 4°C overnight. Secondary antibody incubation was at room temperature for 1 hour. 
Primary antibodies used in this study were phospho-S139 H2AX (Molecular Probes, 1:1000), 
H2AX (CST, Danvers, MA, 1:1000), Caspase 3 (CST,Danvers, MA, 1:1000), Cleaved Caspase 3 
(Asp175) (CST, Danvers, MA,1:800), Mouse anti- ß-actin (1:30,000, Sigma); IRdye680 or 800 
conjugated donkey anti-mouse or rabbit IgG (1: 40,000), LI-COR, Lincoln, NE). 
 
Bioluminescence recordings of intracranial xenografts in vivo: NCR nude mice bearing 
intracranial xenografts of CMV-luc-expressing U87 cells were injected with 150 Ag/g D-
luciferin (Biosynth, Itasca, IL) as previously described [137]. After anesthesia using 2.5% 
isoflurane, mice were imaged with a charge-coupled device camera-based bioluminescence 
imaging system (IVIS 50; Xenogen; exposure time 1-30 s, binning 8, field of view 12, f/stop 1, 
open filter). Signals were displayed as photons/s/cm2 /sr [44]. Regions of interest were defined 
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manually and images were processed using Living Image and IgorPro Software (Version 2.50) as 
described [137]. Raw data were expressed as total photon flux (photons/s; [139]). 
Bioluminescence is reported in the paper as a normalized value, dividing all bioluminescence 
values by the bioluminescence measured at 1 week post tumor implantation. 
Bioluminescence recordings of flank tumors in vivo: Adult NCR nude male mice bearing 
subcutaneous flank mes-GBM xenografts were synchronized to a 12-h light/12-h dark cycle for 
at least 2 weeks (lights on from 7:00 A.M. to 7:00 P.M. (LD)). On the first day of imaging, each 
mouse was anesthetized with isoflurane (2% vaporized in O2) at 6:00 A.M., injected i.p. with d-
luciferin (150 ug/g body weight; Biosynth, Itasca, IL) One minute exposures were captured 10 
minutes after d-luciferin injection. Every 4 h, the mice were reanesthetized with isoflurane and 
imaged with an ultra-sensitive CCD camera in a light tight box (Stanford Photonics; bin factor, 
2; 1/f stop; open filter; Stanford Photonics, Palo Alto, CA). Mice received subcutaneous saline 
for hydration (0.5 cc every 8 hours), were returned to their cages, and awoke within 3 min after 
removal of the anesthetic. This procedure was repeated every 4 h for 48 h, during which time the 
mice showed no adverse effects of repeated 20-min anesthesia.  
Statistical Analysis: Statistical analyses were performed using Prism software. Outliers within 
technical replicates for bioluminescent imaging were excluded using Grubbs’ Test. Analysis of 
rhythmicity of Per2-luc bioluminescence was performed using JTK Cycle, software created by 
Michael Hughes [140].  
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Results 
Bmal1-luc bioluminescence is higher in the morning in vivo 
 We have already demonstrated circadian rhythms in clock gene expression in U87 cells 
in vitro. Our next step was to determine whether clock gene expression rhythms in U87 cells are 
maintained in vivo. To test the hypothesis that clock gene expression continues to oscillate in 
vivo, we measured bioluminescence from nude mice bearing intracranial U87 Bmal1-luc-
expressing xenografts. We saw greater Bmal1-luc bioluminescence at 9am versus 9pm in two 
mice. These preliminary data demonstrate higher Bmal1-luc expression in the morning compared 
to night time. 
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Figure 4.1. Bmal1-luc expression is higher in the morning. A) Bright field images of mice 
with bioluminescence overlay shows relative Bmal1-luc bioluminescence when imaging mice at 
9am versus 9pm. B) Bar graph shows bioluminescence from each U87 Bmal1-luc tumor-bearing 
mouse at 9am versus 9pm (photons/sec, n=2). 
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TMZ-induced growth inhibition of U87 xenografts did not vary in a time of day-dependent 
manner 
 Our U87 in vitro studies have shown a correlation between the peak of Bmal1-luc 
expression and highest sensitivity to TMZ. With the knowledge that Bmal1 expression is higher 
in the morning in intracranial U87 xenografts, we hypothesized that U87 tumors would be more 
sensitive to TMZ in the morning. To test this hypothesis, we treated U87 CMV-luc tumor-
bearing mice with TMZ by oral gavage at 7am or 7pm for 5 consecutive days two weeks and six 
weeks after tumor implantation. We followed tumor growth over time by weekly imaging of 
CMV-luc bioluminescence, which correlates very closely with tumor burden, as assessed by 
MRI [141]. In Cohort 1, we saw very similar growth patterns between the 7AM and 7PM 
treatment groups (Figure 4.2A), but the overall growth of intracranial U87 xenografts over time 
was not significantly different between the 7AM and 7PM treatment groups (ANOVA, p > 0.05). 
Cohort 2 the tumor burden of the 7PM TMZ-treated group was statistically significantly higher 
than the 7AM TMZ group (Figure 4.2B, ANOVA, p < 0.05). In Cohort 3, we treated mice with 
either TMZ or vehicle (DMSO) at 7AM or 7PM using the same treatment schedule as the first 
two cohorts. Cohort 3 revealed a significantly greater reduction of tumor burden in the 7AM 
TMZ group compared to the 7PM TMZ group (Figure 4.2C, ANOVA, p < 0.05). In Cohorts 1 
and 2, there was a brief reduction in tumor burden after TMZ treatment (Figure 4.2A&B). In 
contrast to the first to cohorts, Cohort 3 showed a long-lasting, significant reduction in tumor 
burden after TMZ treatment. There was a reduction in tumor burden in some mice in the DMSO 
treatment groups, suggesting that the biology of the Cohort 3 xenografts is different from the 
biology of the xenografts in the first two cohorts. Two out of 3 cohorts demonstrated a greater 
reduction in tumor burden in the 7AM TMZ treatment groups compared to 7PM TMZ. 
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TMZ Chronotherapy does not alter overall survival of U87 xenograft-bearing mice 
 The overall survival of mice varied among the three cohorts, but never showed a 
significant difference in survival between 7AM and 7PM treatment groups. Cohort 1 shows 
almost completely overlapping survival curves for the two treatment groups (Figure 4.2D,Log-
rank test, p > 0.05). Cohort 2 shows a trend toward longer survival for the 7AM treatment group, 
but the trend is not significant (Figure 4.2E, Log-rank test, p > 0.05). All TMZ-treated mice 
survived for the duration of the study (data not shown), unlike the other two cohorts, and the 
TMZ response we have previously published [138]. When the survival of all three cohorts was 
combined, there was no difference in overall survival based on time of day of treatment. Taken 
together, we have seen variability in survival among the three cohorts with no statistically 
significant difference in survival based on the timing of TMZ administration. 
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Figure 4.2. Chronotherapy of U87 intracranial xenografts yielded variable tumor growth 
and no significant difference in overall survival for morning versus evening. Graphs of fold 
change in CMV-luciferase bioluminescence, a measure of tumor burden, varied among 3 
independently treated cohorts of mice (A-C). Survival for individual cohorts 1 (D) and 2 (E) 
show no significant different in overall survival (Log-rank test, p > 0.05). All TMZ-treated mice 
in cohort 3 survived (survival curve not shown). F) Combined survival of all cohorts was not 
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significantly different when comparing 7AM vs 7PM TMZ treatment (Log-rank test, p > 0.05). 
7AM treatment group (blue) and 7PM treatment group (black) combined all 3 cohorts. Each red 
bar represents one treatment cycle (5 days). TMZ was delivered 2 and 6 weeks after tumor 
implantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[111] 
 
Loss of Bmal1 enhances tumorigenesis 
 To determine whether tumor growth rates differed between Bmal1 WT and Bmal1 KO 
flank tumors, we measured tumor volumes over time. The Bmal1 WT Mes-GBM astrocyte 
implants did not grow over time (Figure 2A). However, the Bmal1 KO Mes-GBM astrocytes 
tumor volumes increased rapidly over time, achieving a 4.5-fold increase in mean tumor volume 
9 weeks after implantation (Figure 2A, p < 0.0001). These data demonstrate that Bmal1 KO Mes-
GBM astrocytes have a greater ability to form tumors than the Bmal1 WT Mes-GBM astrocytes.  
Circadian regulation of gene expression is Bmal1-dependent in vivo 
 After characterizing the cell-intrinsic rhythms of the Mes-GBM astrocytes in vitro, we 
implanted these cells subcutaneously to determine whether our tissue culture results would 
persist in the more complex in vivo environment. We began by characterizing the clock gene 
expression of the Mes-GBM astrocyte flank tumors using the Per2-luc bioluminescent reporter. 
Every 4 hours across 36 hours, we anesthetized Bmal1 WT and Bmal1 KO flank tumor-bearing 
mice, injected d-luciferin, then measured bioluminescence with a low-light imaging system. We 
saw a circadian oscillation in Bmal1 WT Mes-GBM astrocytes with a 2.3-fold change in mean 
bioluminescence from Per2-luc trough to peak.  Per2-luc peak occurred at ZT 15 (10PM) on two 
consecutive days for Bmal1 WT implants. We used JTK Cycle to assess whether the Per2-luc 
was rhythmic over time and determined that Bmal1 WT, but not Bmal1 KO, flank tumors were 
rhythmic (Figure 4.3B; JTK p-value < 0.05; n = 10). In contrast, we saw a lack of circadian 
rhythmicity in Per2-luc bioluminescence in Bmal1 KO flank tumors over time (Figure 4.5A; 
JTK p-value > 0.05, n = 8).  This demonstrates a cell-intrinsic Bmal1-dependent regulation of the 
molecular clock.  
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 To verify that loss of rhythmic Per2-luc bioluminescence reflects a loss of circadian 
regulation of endogenous clock gene expression, we performed RT-qPCR on Bmal1 KO flank 
tumors harvested at 4 different circadian times across the day. To directly test the correlation 
between endogenous Per2 transcription and Per2-luc expression, we measured Per2 mRNA 
levels. As a negative, noncycling control, we measured β-actin mRNA levels. We chose two 
additional target genes based on their rhythmic expression profiles in the CircaDB database 
(http://circadb.hogeneschlab.org/). Atm is rhythmically expressed in mouse kidney in this 
database (JTK Cycle, p < 0.05, period = 26.0 h). Ppp1r3c, a gene highly expressed in glia, was 
also rhythmic in mouse pituitary in this database (JTK Cycle, p < 0.05, period = 24.0 h). The 
change in mean expression levels across time was not statistically significant for any of these 
genes. These qPCR data demonstrate a lack of rhythmic gene expression in Bmal1 KO tumors in 
vivo.  
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Figure 4.3. Bmal1 KO flank tumors lose rhythmic clock gene expression and have 
enhanced tumorigenesis in vivo. A) Subcutaneous implants of Bmal1 WT Mes-GBM astrocytes 
did not form tumors (n = 25). Subcutaneous implantation of Bmal1 KO Mes-GBM astrocytes led 
to rapid tumor growth in vivo (n = 28). Statistical analyses demonstrate significant difference in 
flank tumor size between Bmal1 WT and KO (**** = p<0.0001), and significant growth from 
2.5 weeks to 7 weeks (* = p<0.05), 8 and 9 weeks (**** = p<0.0001). B) Bmal1 WT Mes-GBM 
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astrocytes had circadian rhythms in median Per2-luc bioluminescence across 36 hours, reaching 
peak expression at ZT 15 (10 pm) (JTK Cycle, p-value < 0.05, n = 10). Bmal1 KO Mes-GBM 
astrocytes had arrhythmic Per2-luc bioluminescence (JTK Cycle, p-value > 0.05 n = 8). C-F) 
RT-qPCR of mRNA levels in Bmal1 KO tumors harvested in triplicate every 6 hours across 
zeitgeber time (ZT) showed no significant difference in mRNA expression levels across time for 
Per2 (C), beta-actin (D), Atm (E), or Ppp1r3c (F) using the delta-delta Cq method (One-way 
ANOVA, p > 0.05, n = 3 per time point).  
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Bmal1 KO Mes-GBM tumors lack a circadian rhythm in TMZ sensitivity in vivo 
 After demonstrating dysregulated clock-controlled gene expression in the Bmal1 KO 
tumors, we tested the hypothesis that Bmal1 KO Mes-GBM tumors would lack rhythmic TMZ 
sensitivity in vivo. As we have demonstrated previously [138], TMZ treatment causes a brief 
plateau in GBM growth in vivo. To test whether the timing of TMZ treatment would alter the 
duration of TMZ-induced growth inhibition, we treated nude mice with TMZ or DMSO (12AM 
or 12PM) four weeks after subcutaneous Mes-GBM astrocyte implantation. Flank tumor 
volumes were measured 2-3 times per week after treatment. Cohort 1 (Figure 4.4A) showed a 
brief plateau in flank tumor growth that was greater in the 12PM TMZ treatment group 
compared to 12AM TMZ. In contrast, Cohort 2 showed no difference in growth between the two 
treatment groups (Figure 4.4B). There was no significant difference in tumor growth between 
DMSO- and TMZ-treated Bmal1 KO tumors in Cohort 1 (Figure 4.4C). However, in Cohort 2 
the growth rates of the TMZ-treated Bmal1 KO tumors was significantly less than the growth of 
the DMSO-treated tumors (Figure 4.4D, ANOVA, p < 0.05).  Overall, there was no consistent 
difference in long-term Bmal1 KO tumor growth following treatment at 12AM versus 12PM.  
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Figure 4.4. Long-term Mes-GBM Bmal1 KO flank tumor growth after TMZ 
chronotherapy in vivo. TMZ-induced growth inhibition of flank tumors was measured by 
digital caliper measures. The first 1.5 weeks after treatment for cohort 1 (A) and cohort 2 (B) are 
shown with 12AM TMZ-treated tumors in black and 12PM TMZ-treated tumors in orange, with 
the red bar representing 5 days of TMZ treatment (n=3 per group). Long-term growth curves of 
cohort 1 (C) and cohort 2 (D) show four treatment groups: 12AM TMZ (black square), 12PM 
TMZ (orange triangle), 12AM DMSO (gray open square), and 12PM DMSO (gray open 
triangle).  
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We examined acute TMZ sensitivity in the Bmal1 KO tumors. To test whether the 
rhythms in H2AX phosphorylation and caspase cleavage we observed in vitro persist in vivo, we 
treated mice bearing Bmal1 KO Mes-GBM flank tumors with TMZ or DMSO at 2 different 
times of day: 12AM or 12PM. These times were chosen based on preliminary Per2-luc rhythms 
obtained from Bmal1 WT Mes-GBM subcutaneous implants, which reached peak Per2-luc 
expression at 2AM (data not shown).  Mice were treated once per day, at 12AM or 12PM, for 5 
consecutive days. Bmal1 KO tumor tissue was harvested at 24 h or 36 h after the final treatment. 
Western blots of histone-extracted tumor tissue were probed for phospho- and total H2AX 
(Figure 4.5A). Phospho-H2AX was normalized to total H2AX protein for each sample and fold 
change in H2AX phosphorylation was determined by dividing TMZ-treated tumors by DMSO-
treated control tumors. There was no significant different in TMZ-induced phosphorylation of 
H2AX between the 12AM and 12PM treatment groups for tissue harvested at 24 h or 36 h post-
treatment (Figure 4.5B & C). Westerns of tumor tissue lysate were probed for cleaved caspase-3 
and beta-actin (Figure 4.5D). Cleaved caspase-3 was normalized to beta-actin for each sample 
and fold change in caspase-3 cleavage was determined by dividing TMZ-treated tumor samples 
by their DMSO-treated controls. There was no significant difference in caspase-3 cleavage 
between the 12AM and 12PM treatment groups, regardless of the time of tissue harvest (Figures 
4.5E & F). These data demonstrate a lack of rhythmicity in acute TMZ sensitivity in Bmal1 KO 
Mes-GBM astrocytes in vivo. 
The clock gene expression in human intracranial U87 xenograft and Bmal1 WT Mes-
GBM flank implants changed in a time of day-dependent manner. Loss of Bmal1 caused 
arrhythmic expression of clock-controlled genes in the Mes-GBM astrocytes, in vivo. TMZ-
induced inhibition of intracranial U87 and Bmal1 KO Mes-GBM flank tumor growth did not 
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vary based on timing of TMZ administration. In both sets of experiments, there was a high 
degree of variability in tumor growth after treatment. Taken together, these data demonstrate an 
absence of time of day-dependent TMZ sensitivity of GBM tumors in vivo.  
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Figure 4.5. Acute DNA damage response and activation of apoptosis does not change with 
chronotherapy in vivo. Representative Western blots of phospho-H2AX (A) and cleaved 
caspase-3 (D) were quantified in panels B&C and E&F, respectively. B) Bmal1 KO tumors 
harvested 24 hours after the fifth and final dose of TMZ showed no difference in 
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phosphorylation of H2AX between 12AM and 12PM TMZ treatment groups (Student’s T-test, p 
> 0.05). C) Bmal1 KO tumors harvested 36 hours after the fifth and final dose of TMZ showed 
no difference in phosphorylation of H2AX (Student’s T-test, p > 0.05). E) TMZ-induced 
cleavage of caspase-3 was not significantly different between treatment groups for tumors 
harvested 24 hours after the final TMZ treatment (Student’s T-test, p > 0.05). F) TMZ-induced 
cleavage of caspase-3 was not significantly different between treatment groups for tumors 
harvested 36 hours after the final TMZ treatment (Student’s T-test, p > 0.05). 
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Discussion 
The in vitro characterization of the Bmal1-dependent rhythms in gene expression and 
susceptibility to TMZ described in the previous chapters of this thesis has helped us understand 
more about the molecular clock in glioblastoma, but we also need to understand these rhythms in 
the context of a more complex in vivo system. Does rhythmic clock gene expression persist in 
vivo? If so, are these rhythms Bmal1-dependent? Are there times of day-dependent oscillations in 
TMZ sensitivity in vivo? Answering these questions will help us determine how readily our in 
vitro observations can be translated to clinical treatments of GBM patients.   
We are the first group to demonstrate circadian rhythms in clock gene expression in 
glioma cells in vivo. We have shown higher Bmal1-luc expression at 9am versus 9pm in 
intracranial U87 xenografts. Alone, the Bmal1-luc U87 data do not demonstrate a rhythm, only a 
morning versus evening difference. With more frequent sampling, we have demonstrated a 
rhythm in Per2-luc expression over time in Bmal1 WT Mes-GBM astrocytes in vivo. Our results 
are consistent with rhythmic clock gene expression in flank tumor xenografts of a human 
fibrosarcoma cell line, which also reached peak Per2-luc expression during the night [142]. 
Comas and colleagues showed the phase of Per2 expression in their tumors was similar to the 
phases of Per2 expression in liver, lung and spleen within the same mouse. The rhythmic 
expression of Per1-luc in rat olfactory bulb [143] and Per2-luc in mouse olfactory bulb [144] 
show circadian rhythms in clock gene expression with phases that are consistently in anti-phase 
with the Bmal1-luc expression we showed in the intracranial U87 xenografts. Taken together, 
these data demonstrate rhythmic clock gene expression in GBM tumors in vivo, with peak 
expression occurring at a time of day consistent with clock gene expression data previously 
reported in other tissues. 
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The loss of rhythmic Per2-luc bioluminescence in the Bmal1 KO Mes-GBM flank tumors 
demonstrates a Bmal1-dependent regulation of clock gene expression in vivo. RT-qPCR data 
showing a lack of rhythm in the mRNA expression levels of clock controlled genes (CCGs) 
Per2, Atm and Ppp1r3c provide further support for the loss of rhythmic expression of CCGs in 
the Bmal1 KO Mes-GBM tumors. It is important to recognize that we do not show rhythmic 
expression of CCGs in Bmal1 WT Mes-GBM flank tumors. The RT-qPCR data would be 
stronger if we had demonstrated rhythmic expression of CCGs in Bmal1 WT tumors and a loss 
of rhythmic expression in the Bmal1 KO tumors. However, we did not have enough tissue from 
the Bmal1 WT implants to perform RT-qPCR. When we combine the RT-qPCR results with the 
similarly arrhythmic expression of Per2-luc in the Bmal1 KO flank tumors, we create a stronger 
argument for the loss of circadian regulation of CCG transcription in the absence of Bmal1. This 
outcome is consistent with our in vitro data. However, it conflicts with data from Pando and 
colleagues, demonstrating a restoration of circadian rhythms in clock gene expression in 
Clock/Clock mutant mouse embryonic fibroblasts implanted subcutaneously in mice with intact 
circadian rhythms in healthy tissue [145]. The host signal responsible for restoring rhythmic 
clock gene expression in Clock/Clock mutant MEFs is either absent or insufficient to restore 
rhythms in the Bmal1 KO Mes-GBM astrocytes. Taken together, these data demonstrate the 
persistence of rhythmic clock gene expression in the Mes-GBM astrocytes in vivo, with Bmal1-
dependent regulation of rhythmic CCG expression. Further research is needed to help us 
reconcile the discrepancy between our findings and those of Pando and colleagues.   
The TMZ chronotherapy studies in U87 xenograft-bearing mice showed inconsistent anti-
tumor activity and no significant changes in overall survival based on the timing of TMZ 
administration. Intracranial U87 xenografts in two out of three cohorts showed a greater 
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reduction in tumor burden in mice treated with TMZ at 7AM versus 7PM. Despite these 
differences in tumor burden, we never saw significant changes in overall survival. It is possible 
that two cycles of TMZ was insufficient to change overall survival. Additional treatment cycles 
or higher TMZ doses may alter survival. This outcome is inconsistent with two rodent 
chronotherapy trials, showing increased tumor regression and improved survival following day 
time treatment with doxorubicin or early night time treatment with oxaliplatin [134, 135]. Since 
these trials used different chemotherapies to treat different tumor types, there are many reasons 
why our data are inconsistent with their outcomes. Based on these data, we cannot conclude a 
presence or absence of daily rhythms in TMZ anti-tumor activity in GBM in vivo. We have 
demonstrated a lack of change in survival in our U87 intracranial xenograft model of GBM. 
Future studies should try higher doses of TMZ at a greater variety of treatment times throughout 
the day to find the optimal benefit of TMZ therapy for GBM. 
Following up on these early U87 xenograft studies, we examined the in vivo TMZ 
sensitivity of GBM flank tumors lacking a functional clock. We showed a lack of time of day-
dependent TMZ sensitivity in the Bmal1 KO Mes-GBM flank tumors when measuring acute 
tumor responses to TMZ and long-term growth inhibition in BMAL1 KO flank tumors following 
TMZ chronotherapy. The Bmal1 WT Mes-GBM flank implants did not form tumors, so we were 
unable to test the TMZ sensitivity of those GBM cells in vivo. Due to the lack of parallel studies 
in Bmal1 WT Mes-GBM flank tumors, we cannot conclude that the lack of time of day-
dependent sensitivity of Bmal1 KO Mes-GBM flank tumors is a loss of rhythm. If the Bmal1 WT 
flank tumors had grown, they may have also shown no difference in TMZ sensitivity based on 
the timing of treatment. Two rodent chronotherapy trials demonstrated minimal antitumor 
activity of cisplatin at all treatment times in a rats with plasmacytoma and mice with pancreatic 
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adenocarcinoma, regardless of the timing of treatment [135]. We will learn more about the 
importance of the clock within the tumor by performing future studies in a GBM model system 
where we can directly compare Bmal1 WT and Bmal1 KO TMZ chronotherapy responses in 
vivo.  
Very few studies have demonstrated a role for the molecular clock in regulating the 
sensitivity to chemotherapy in vivo. Gorbacheva and colleagues demonstrated time of day-
dependent rhythms in cyclophosphamide toxicity in mice. They ablated these daily rhythms in 
toxicity and increased total toxicity in Bmal1 KO and Clock/Clock mutant mice [146]. Although 
this study only looked at toxicity in the healthy host tissue, it provides insight into the circadian 
regulation of chemotherapy. In contrast, overexpression of Bmal1 in colon cancer flank tumors 
increased the sensitivity of these flank tumors to oxaliplatin [69]. Together, these data may 
demonstrate that disruption of the normal oscillations of the clock, through knockout or 
overexpression, increase sensitivity to chemotherapy.  
Chronotherapy has improved clinical outcomes for a variety of cancers. However, this 
study provides the first application of chronotherapy to brain tumors. These data provide a 
foundation on which to build a strong case for the application of chronotherapy to brain tumor 
patients. Our current data suggest a role for Bmal1 in maintaining circadian oscillations in gene 
expression in vivo. The intracranial and subcutaneous xenograft studies provide insufficient 
evidence that TMZ chronotherapy will improve tumor growth inhibition or survival in the 
context of a tumor-bearing host. It is possible that the circadian rhythms we have demonstrated 
in TMZ sensitivity in vitro may not result in improved treatment outcomes in the context of the 
complex in vivo environment. However, we have not proven a lack of rhythm in TMZ sensitivity 
in vivo. Future studies may need to use more sensitive methods of measuring anti-tumor efficacy, 
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or try treating with higher doses at a greater variety of time points throughout the day in order to 
discover the optimal timing of TMZ therapy. 
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 The poor prognosis of GBM has motivated a number of scientists and clinicians to seek 
novel therapeutic strategies to fight these high grade gliomas. The addition of temozolomide 
(TMZ) increased median survival by 2.5 months over surgery and radiation alone. Additional 
lengthening of median survival by an additional 2.5 months or more would be a breakthrough in 
GBM treatement. Improvement of clinical outcomes in the treatment of other cancers has been 
achieved by timing the administration of chemotherapy to biological rhythms, a technique 
known as chronotherapy. This thesis extends the application of chronotherapy to gliomas for the 
first time in order to enhance treatment outcomes using temozolomide, a drug currently used as 
standard therapy for high grade gliomas. In light of the success of chronotherapy for other 
cancers, this thesis attempts to answer four questions: 1) What are the characteristics of the 
molecular clock in glioma cells? If there is an intact clock in glioma cells, 2) Is there a time of 
day-dependent oscillation in TMZ sensitivity? 3) If a rhythm exists, is it dependent upon a 
functional molecular clock? 4) If we identify rhythms in TMZ sensitivity in vitro, will those 
rhythms persist in vivo? Through a series in vitro and in vivo experiments, this study 
demonstrates circadian rhythms in clock gene expression. This study also demonstrates a Bmal1-
dependent GBM tumor cell-intrinsic sensitivity to temozolomide (TMZ) that oscillates in a time 
of day-dependent manner in vitro. However, our current studies to do not demonstrate a 
persistence of this rhythmic sensitivity in vivo. Further work needs to be done to evaluate the 
circadian rhythms in TMZ sensitivity of GBM in vivo.  
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Circadian oscillations in clock gene expression in GBM in vitro and in vivo 
 Daily oscillations in Per2 and Bmal1 luciferase reporters in U87 and Mes-GBM 
astrocytes demonstrated that glioma cells have an intact molecular clock in vitro. Many human 
cancer cell lines that have been tested do not have rhythmic clock gene expression (Robert 
Dallman and John Hogenesch, personal communication). Clock gene expression in U87 cells and 
Mes-GBM astrocytes had average periods of 24.5 h and 23.3 h, respectively, showing reliable 
near-24 hour rhythms in clock gene expression in vitro. Anti-phase oscillations of Per2-luc and 
Bmal1-luc, with peaks occurring 12.1 hours apart on average, demonstrate canonical regulation 
of the molecular clock within the U87 cells. In contrast, the average time between Bmal1 and 
Per2 peaks in Mes-GBM astrocyte cultures is 8.8 ± 2.1 h, demonstrating that Bmal1 and Per2 
are often, but not always, expressed in anti-phase in vitro. This imperfect phase relationship 
between the positive and negative arms of the molecular clock may have contributed to 
variations between replicate experiments.  Overall, these data demonstrate reliable circadian 
oscillations in gene expression in two different glioma cultures in vitro. 
Bioluminescence imaging of Bmal1 and Per2 reporters showed diurnal rhythms in clock 
gene expression in two in vivo GBM models. We demonstrated higher Bmal1-luc expression at 
9AM versus 9PM in U87 intracranial xenografts, which only supports a day-night difference in 
Bmal1 expression. With more frequent sampling, we demonstrated Per2-luc rhythms in Bmal1 
WT Mes-GBM astrocyte subcutaneous implants. By sampling every 4 hours across 36 hours, we 
were able to demonstrate peak Per2 expression at 10PM (ZT 15) on two consecutive days. High 
Bmal1 expression in U87 xenografts in the morning and high Per2 expression at night in Mes-
GBM flank implants supports an anti-phase relationship between Bmal1 and Per2 expression in 
GBM in vivo. Definitive evidence of an anti-phase relationship between Bmal1 and Per2 in vivo 
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would require imaging Bmal1-luc and Per2-luc-expressing GBM tumors simultaneously in vivo. 
These data support reliable diurnal rhythms in clock gene expression in two models of GBM in 
vivo. To define these clock gene expression rhythms as circadian we would need to house the 
mice in constant darkness before measuring Per2-luc expression in vivo. Our results are 
consistent with rhythmic clock gene expression in flank tumor xenografts of a human 
fibrosarcoma cell line, which also reached peak Per2 expression during the night [142]. 
Together, these data demonstrate a diurnal rhythm in clock gene expression in GBM cells in 
vivo. 
We next examined the phase relationships of clock gene expression in the GBM cells to 
neighboring tissues in vivo. The rhythmic expression of Per1-luc in rat olfactory bulb [143] and 
Per2-luc in mouse olfactory bulb [144] show circadian rhythms in clock gene expression with 
phases that are consistently in anti-phase with the Bmal1-luc expression we showed in the 
intracranial U87 xenografts. We have also demonstrated Per2 rhythms in the skin of Per2-luc 
knock-in mice with peak expression at 11PM (ZT16), near the time of peak Per2 expression in 
the Bmal1 WT tumors. These data are consistent with a publication showing similar phases of 
Per2 expression in colon cancer cell flank tumors and liver, lung and spleen within the same 
mouse [142]. Taken together, these data demonstrate similar phases of clock gene expression in 
GBM cells and neighboring healthy host cells in vivo. 
The phase relationship we observe between GBM cells and host tissue suggests, but does 
not prove that GBM cells entrain to host rhythms. To test the hypothesis that GBM cells entrain 
to host rhythms, future studies would need to house GBM tumor-bearing mice in shifting 
lighting schedules. If the GBM cells entrain to host rhythms, a shift in the lighting schedule 
would shift clock gene expression rhythms in the tumor. Comas and colleagues were able to shift 
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Bmal1 and Per2 expression in fibrosarcoma flank tumors by entraining the mice to a restricted 
feeding schedule [142]. We could adopt their protocol and restrict feeding to the day (rest) time 
for the mice and assess rhythms in Per2-luc after their activity rhythms have entrained to the new 
feeding schedule. Current evidence suggests GBM rhythms are synchronized to the host, but 
further research is required to determine whether GBM rhythms in clock gene expression can be 
entrained to host rhythms.  
The loss of rhythmic Per2-luc expression in the Bmal1 KO Mes-GBM flank tumors 
demonstrates a Bmal1-dependent regulation of clock gene expression in vivo. RT-qPCR data 
showing a lack of rhythm in the mRNA expression levels of clock controlled genes (CCGs) 
Per2, Atm and Ppp1r3c provided further support for the loss of rhythmic expression of CCGs in 
the Bmal1 KO Mes-GBM tumors. It is important to recognize that we do not show rhythmic 
expression of CCGs in Bmal1 WT Mes-GBM flank tumors. The RT-qPCR data would be 
stronger if we had demonstrated rhythmic expression of CCGs in Bmal1 WT tumors and a loss 
of rhythmic expression in the Bmal1 KO tumors. However, we did not have enough tissue from 
the Bmal1 WT implants to perform RT-qPCR. When we combine the RT-qPCR results with the 
similarly arrhythmic expression of Per2-luc in the Bmal1 KO flank tumors, we create a stronger 
argument for the loss of circadian regulation of CCG transcription in the absence of Bmal1. This 
outcome is consistent with our in vitro data, demonstrating a loss of Per2-luc rhythms in Bmal1 
KO Mes-GBM astrocytes. However, it conflicts with data from Pando and colleagues, 
demonstrating a restoration of circadian rhythms in clock gene expression in Clock/Clock mutant 
mouse embryonic fibroblasts (MEFs) implanted subcutaneously in mice with intact circadian 
rhythms in healthy tissue [145]. The host signal responsible for restoring rhythmic clock gene 
expression in Clock/Clock mutant MEFs is either absent or insufficient to restore rhythms in the 
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Bmal1 KO Mes-GBM astrocytes. Taken together, these data demonstrate the persistence of 
rhythmic clock gene expression in the Mes-GBM astrocytes in vivo, with Bmal1-dependent 
regulation of rhythmic CCG expression. Further research is needed to help us reconcile the 
discrepancy between our findings and those of Pando and colleagues.   
Time of day-dependent rhythms in response to temozolomide treatment in 
vitro 
This thesis demonstrates cell-intrinsic circadian rhythms in sensitivity of a human U87 
glioblastoma cell line and a mouse model of glioblastoma (Nf1-/-;DNp53 astrocytes) to 
temozolomide (TMZ). The amount of TMZ-induced growth inhibition varied based on the time 
of day of treatment, achieving greatest growth inhibition at the peak of Bmal1 expression in both 
GBM models. Consistent with these findings, we also demonstrated a circadian rhythm in 
activation of apoptosis in Mes-GBM astrocytes, achieving greatest induction of apoptosis when 
treating at the Bmal1 peak. This is consistent with data demonstrating reduced apoptosis 
following Bmal1 knockdown in colon cancer cell lines in vitro [68]. Demonstrating a rhythm in 
TMZ-induced cell death was a promising start, which led us to search for rhythms in response to 
TMZ treatment at a higher level of the DNA damage response pathway.  
We knew TMZ treatment exerted its cytotoxicity through the formation of double strand 
breaks (DSBs), so we examined phosphorylation of histone H2AX at serine 139, an early step in 
the cellular response to DSB formation. We have identified circadian rhythms in TMZ-induced 
phosphorylation of H2AX in both GBM models in vitro. At any point in time, the level of H2AX 
phosphorylation reflects the balance between the sensing of DSBs, which recruits DNA repair 
proteins to sites of damage near phosphorylated H2AX, and DNA repair, which causes 
dephosphorylation of H2AX. With this in mind, there are several potential interpretations of the 
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data. First, the oscillations in phospho-H2AX may reflect a daily rhythm in the number of DSBs 
induced by TMZ. Second, these oscillations may result from rhythms in ATM-induced 
phosphorylation of H2AX following induction of DNA damage. Third, these oscillations may 
reflect a time of day-dependent rhythm in the kinetics of DNA repair and dephosphorylation of 
H2AX. It is also possible that the rhythm we measure is a combination of rhythms in two or 
more of these processes. There are currently no publications demonstrating a circadian rhythm in 
H2AX phosphorylation. However, there are studies supporting the enhanced ATM-dependent 
phosphorylation of Chk2 following overexpression of Per1 or Per3 [70, 71]. It is possible that the 
enhanced interactions of ATM with Chk2 reduce the availability of ATM to phosphorylate 
H2AX, but there is currently no evidence to support this hypothesis. Further studies are needed 
to understand how components of the core molecular clock regulate H2AX phosphorylation.  
At every level where we have tested for rhythms in TMZ sensitivity, we have found 
them. We have seen a consistent correlation between the peak of Bmal1 and the maximal 
measures of H2AX phosphorylation, caspase activity and growth inhibition. Consistent with our 
studies, Dulong and colleagues demonstrated an endogenous circadian rhythm in irinotecan-
induced cytotoxicity in colon cancer cells with greatest cytotoxicity occurring at the peak of 
Bmal1 expression in vitro. Taken together, these studies correlate Bmal1 expression with 
sensitivity to DNA damaging agents in tumor cells.  
Where does the cell-intrinsic rhythm in TMZ response originate? 
We have characterized the circadian rhythm in TMZ sensitivity in our GBM model 
system, but we have not yet identified a specific mechanism that creates the rhythm. One 
possible explanation of the consistent rhythms measured at the levels of DNA repair, apoptosis 
and growth inhibition is that the molecular clock could directly regulate the DNA damage 
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response at many levels simultaneously. Or, we could interpret our observations of a rhythm at 
the levels of DNA repair and apoptosis as the reflections of a rhythm created at a single point 
early in the pathway. These rhythms could originate at the level of DNA repair, but we cannot 
draw that conclusion based on current results.   
We have not yet ruled out the possibility that rhythms in the amount of DNA damage 
induced by TMZ at different times of day may underlie the circadian rhythms we have observed 
in TMZ sensitivity.  Clock knockdown increased the amount of radiation-induced DNA damage 
in U87 cells [147]. In contrast, Bmal1 knockdown reduced cisplatin-induced DNA damage in 
colon cancer cell lines [68]. Despite the conflicting results from these two studies, both 
demonstrated links between the molecular clock and induction of DNA damage. A rhythm in cell 
cycle regulation could create an oscillation in the number of TMZ-induced DNA double strand 
breaks. In future studies, quantifying EdU incorporation at each of the 4 circadian times of 
treatment would tell us whether or not there is a rhythm in cell cycle progression through S 
phase. If this experiment identifies a rhythm in EdU incorporation, it would provide an 
opportunity for more double strand breaks to occur at the time of day when the largest 
percentage of tumor cells are in S phase.  Several cell cycle regulators have already been 
identified as clock controlled genes. So, it is possible that circadian rhythms exist in the 
regulation of cell cycle progression in the Mes-GBM astrocytes. Another possible mechanism 
underlying rhythmic TMZ sensitivity is the TMZ concentration within tumor cells at different 
times of day. Rhythms in the expression or activity of drug efflux pumps could alter intracellular 
TMZ concentrations, causing a rhythm in the amount of TMZ-induced DNA damage. Dulong 
and colleagues recently demonstrated a rhythm in pharmacokinetics of irinotecan underlying 
circadian sensitivity to the drug in vitro [94]. Further evaluation is required to determine whether 
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the rhythm in TMZ sensitivity exists at the level of DNA damage induction or regulation of the 
response to DNA damage.  
Role of Bmal1 in temozolomide sensitivity 
To test whether the circadian oscillation in TMZ-induced growth inhibition was created 
by a rhythm in cell death, we examined the activation of the apoptotic pathway in response to 
TMZ treatment at different times of day. TMZ-induced DNA damage led to a time of day-
dependent rhythm in apoptosis in the Mes-GBM astrocytes. The bioluminescent caspase 3/7 
activity reporter used in Figure 4 shows highest caspase 3 activity at the peak of Bmal1 
expression. Because caspases 3 and 7 are downstream effector caspases in the apoptotic 
pathway, their activation irreversibly leads to programmed cell death [148]. Therefore, the time 
of day-dependent oscillation observed in TMZ-induced caspase 3 and 7 activity demonstrates a 
circadian rhythm in apoptotic cell death. The loss of rhythmic activation of apoptosis in Bmal1 
KO Mes-GBM astrocytes demonstrated that Bmal1 was required for creating this rhythm. All 
evidence in the literature supporting circadian regulation of apoptosis involves genetic 
manipulation of clock gene expression. These findings are consistent with reports of reduction in 
etoposide-induced apoptosis of colon cancer cells after Bmal1 knockdown [68]. Bmal1 
knockdown also led to reduced irinotecan-induced apoptosis [94]. In contrast, a number of 
studies have demonstrated increased expression of Period genes with increased apoptosis. Per1 
overexpression increased the rate of apoptosis in response to ionizing radiation [70] and Per2 and 
Per3 overexpression induced increased apoptosis in the absence of DNA-damaging agents [71, 
81]. Taken together, these data show that components of the core molecular clock are capable of 
regulating apoptosis; however, the conflicting outcomes of genetic manipulation of cancer cells 
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in these studies demonstrates the need for further evaluation of the interactions between the 
circadian and apoptotic pathways.  
 Future studies could manipulate Bmal1 expression and function to further characterize 
the role of Bmal1 in DNA damage response. Overexpression of Bmal1 increases sensitivity of 
colon cancer cells to oxaliplatin [69]. Overexpression of Bmal1 in the Mes-GBM astrocytes 
would test the sufficiency of Bmal1 for the induction of high levels of activation of apoptosis. To 
test whether the transcription factor activity of Bmal1 is responsible for regulating TMZ 
sensitivity, we could express Bmal1 with a mutated DNA binding domain in Bmal1 KO Mes-
GBM astrocytes. If the binding domain-mutated Bmal1 does not rescue the Bmal1 KO 
phenotype, then we could conclude DNA binding activity of Bmal1 is required for its regulation 
of TMZ sensitivity, likely through the transcriptional activation of one or more clock controlled 
genes. Manipulation of Bmal1 expression and transcriptional activity may provide clues to the 
mechanism that creates circadian oscillations in TMZ sensitivity.  
Bmal1 protein-protein interactions should also be tested to determine if Bmal1 regulates 
susceptibility to TMZ through a DNA binding-independent mechanism. Immunoprecipitation of 
Bmal1 followed by identification of proteins in complex with Bmal1 would provide a list of 
candidates potentially involved in regulating the DNA damage response. There are currently no 
published reports of DNA damage response-related proteins interacting with Bmal1. However, a 
high throughput screen identified Clock as a modulator of DNA damage-induced ATR signaling 
and demonstrated co-localization of CLOCK with phospho-H2AX [149]. This was the first 
report of a direct interaction of the transcription factor Clock with proteins involved in DDR. 
Many studies have assumed that CLOCK and BMAL1 exert their regulation of the response to 
DNA damage solely through transcriptional activity, but that may not be the case. Identification 
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of BMAL1 protein binding partners after induction of DNA damage may help elucidate the key 
regulators of the Bmal1-dependent regulation of TMZ sensitivity rhythms.  
 It is possible that the Bmal1 KO phenotype is related solely to Bmal1’s role as a 
transcription factor, not necessarily as a regulator of the molecular clock. To test the role of the 
molecular clock more directly, we could delete CRY1 and CRY2 to abolish circadian rhythms in 
transcriptional activation of clock-controlled genes. This would get rid of the daily rhythms of 
the molecular clock without hindering the activity of Bmal1. If the results of the CRY1/2 DKO 
studies corroborate the results of our Bmal1 KO studies, it will provide even stronger evidence 
that the Bmal1 -dependent TMZ sensitivity is a molecular clock-dependent rhythm. 
Based on Bmal1 knockout studies performed in other cell types [60, 64, 65], we predicted 
that loss of Bmal1 would lead to loss of daily oscillations in Per2 expression. We have 
demonstrated rhythmic expression of the Per2-luc bioluminescent reporter in vitro. Loss of 
Bmal1 leads to arrhythmic expression of Per2-luc in vitro. We use the Per2-luc reporter as a way 
to detect and measure oscillations in clock-controlled genes. The loss of rhythm in TMZ 
sensitivity in the Bmal1 KO Mes-GBM astrocytes provides an output supporting this assumption. 
It will be important for futures studies to identify specific clock-controlled genes contributing to 
the Bmal1 -dependent rhythmicity in TMZ sensitivity in GBM. Comparing microarray data from 
Bmal1 WT and Bmal1 KO Mes-GBM astrocytes harvested every 2 hours across 48 hours will 
reveal genes with Bmal1 -dependent rhythms in expression. Within the resulting list of genes, 
there are likely to be some genes with known functions related to the DNA damage response. 
These will be candidates for key regulators of the mechanism underlying the circadian regulation 
of TMZ sensitivity observed in Mes-GBM astrocytes in this study.    
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Chronotherapy has improved clinical outcomes for a variety of cancers. However, this 
study provides the first application of chronotherapy to brain tumors. These results provide a 
foundation on which to build a strong case for the application of chronotherapy to brain tumor 
patients.  
Role of Bmal1 in GBM tumorigenesis in vivo 
  We observed enhanced tumorigenesis in the Bmal1 KO Mes-GBM astrocytes in vivo. 
The Bmal1 WT Mes-GBM astrocytes implanted subcutaneously survived for the duration of our 
studies, but did not form tumors. In contrast, the Bmal1 KO Mes-GBM astrocytes formed rapidly 
growing tumors in two independent cohorts of mice. These data are consistent with a study 
showing accelerated growth of colorectal cancer flank tumors with reduced Bmal1 expression 
[68]. Zeng and colleagues also demonstrated that Bmal1 knockdown increased proliferation of 
colorectal cancer cells in vitro [68]. In line with these observations, overexpression of Bmal1 
reduced colorectal cancer flank tumor growth [69]. Taken together, these data demonstrate a role 
for Bmal1 in suppressing cancer cell proliferation and tumorigenesis.  
Temozolomide chronotherapy of GBM in vivo 
The in vitro characterization of the Bmal1-dependent rhythms in gene expression and 
susceptibility to TMZ has helped us understand more about the molecular clock in glioblastoma, 
but we also need to understand these rhythms in the context of a more complex in vivo system. 
Using two mouse models of GBM, we tested whether the rhythms in TMZ sensitivity we 
identified in vitro persisted in vivo.  
The TMZ chronotherapy studies in U87 xenograft-bearing mice showed inconsistent anti-
tumor activity and no significant changes in overall survival based on the timing of TMZ 
administration. Intracranial U87 xenografts in two out of three cohorts showed a greater 
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reduction in tumor burden in mice treated with TMZ at 7AM versus 7PM. Despite these 
differences in tumor burden, we never saw significant changes in overall survival. It is possible 
that two cycles of TMZ was insufficient to change overall survival. Additional treatment cycles 
or higher TMZ doses may alter survival. This outcome is inconsistent with two rodent 
chronotherapy trials, showing increased tumor regression and improved survival following day 
time treatment with doxorubicin or early night time treatment with oxaliplatin [134, 135]. Since 
these trials used different chemotherapies to treat different tumor types, there are many reasons 
why our data are inconsistent with their outcomes. Based on these data, we cannot conclude a 
presence or absence of daily rhythms in TMZ anti-tumor activity in GBM in vivo. We have 
demonstrated a lack of change in survival in our U87 intracranial xenograft model of GBM. 
Future studies should try higher doses of TMZ at a greater variety of treatment times throughout 
the day to find the optimal benefit of TMZ therapy for GBM. 
Following up on these early U87 xenograft studies, we examined the in vivo TMZ 
sensitivity of GBM flank tumors lacking a functional clock. We showed a lack of time of day-
dependent TMZ sensitivity in the Bmal1 KO Mes-GBM flank tumors when measuring acute 
tumor responses to TMZ and long-term growth inhibition in Bmal1 KO flank tumors following 
TMZ chronotherapy. The Bmal1 WT Mes-GBM flank implants did not form tumors, so we were 
unable to test the TMZ sensitivity of those GBM cells in vivo. Due to the lack of parallel studies 
in Bmal1 WT Mes-GBM flank tumors, we cannot conclude that the lack of time of day-
dependent sensitivity of Bmal1 KO Mes-GBM flank tumors is a loss of rhythm. If the Bmal1 WT 
flank tumors had grown, they may have also shown no difference in TMZ sensitivity based on 
the timing of treatment. Two rodent chronotherapy trials demonstrated minimal antitumor 
activity of cisplatin at all treatment times in a rats with plasmacytoma and mice with pancreatic 
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adenocarcinoma, regardless of the timing of treatment [135]. We will learn more about the 
importance of the clock within the tumor by performing future studies in a GBM model system 
where we can directly compare Bmal1 WT and Bmal1 KO TMZ chronotherapy responses in 
vivo.  
Very few studies have demonstrated a role for the molecular clock in regulating the 
sensitivity to chemotherapy in vivo. Gorbacheva and colleagues demonstrated time of day-
dependent rhythms in cyclophosphamide toxicity in mice. They ablated these daily rhythms in 
toxicity and increased total toxicity in Bmal1 KO and Clock/Clock mutant mice [146]. Although 
this study only looked at toxicity in the healthy host tissue, it provides insight into the circadian 
regulation of chemotherapy. In contrast, overexpression of Bmal1 in colon cancer flank tumors 
increased the sensitivity of these flank tumors to oxaliplatin [69]. Together, these data may 
demonstrate that disruption of the normal oscillations of the clock, through knockout or 
overexpression, increase sensitivity to chemotherapy.  
Chronotherapy has improved clinical outcomes for a variety of cancers. However, this 
study provides the first application of chronotherapy to brain tumors. These data provide a 
foundation on which to build a strong case for the application of chronotherapy to brain tumor 
patients. Our in vivo GBM studies provide insufficient evidence that TMZ chronotherapy will 
improve tumor growth inhibition or survival in the context of a tumor-bearing host. It is possible 
that the circadian rhythms we have demonstrated in TMZ sensitivity in vitro may not result in 
improved treatment outcomes in the context of the complex in vivo environment. However, we 
have not proven a lack of rhythmicity in TMZ sensitivity in vivo. Future studies may need to use 
more sensitive methods of measuring anti-tumor efficacy, or treating at a greater variety of time 
points throughout the day in order to discover the optimal timing of TMZ therapy. 
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Clinical Applications of Chronotherapy for Brain Cancer 
Through these studies, we provide a foundation for future applications of chronotherapy 
to brain tumors in additional mouse models and in human GBM patients. Using GBM as a model 
system, we have characterized the role of tumor cell-intrinsic circadian rhythms in response to 
chronomodulated chemotherapy. The results of our studies can be applied to a variety of other 
tumor types in future studies.  
Concepts tested in this thesis can be applied to TMZ treatment of GBM patients in the 
clinic. Based on these studies, we will perform a retrospective study to review chart information 
from GBM patients treated with TMZ in the morning or the evening. We recently discovered that 
two neuro-oncologists at Barnes-Jewish Hospital advised their patients to take their TMZ at two 
different times of day: early in the morning, or at night before bed. We have received IRB 
approval to perform a chart review of these patients. We will compare hematologic toxicity and 
survival in these patients to see if there are statistically significant differences in clinical 
outcomes based on the time of day of treatment. Retrospective studies have some disadvantages; 
the inability to randomize patients to treatment groups creates selection bias in the study, we rely 
on notes in the chart to be detailed and accurate for each patient and we have no way of 
confirming that the patients took the TMZ at the times of day recommended by their neuro-
oncologist. Retrospective studies are not perfect, but they help us gather preliminary information 
to lay the groundwork for future prospective studies. We have also put together a prospective 
trial for future GBM patients at Barnes-Jewish Hospital. The patients will be randomized to 
morning or evening adjuvant TMZ treatments (after the completion of radiation therapy and 
concomitant TMZ). We will monitor quality of life, hematologic toxicity, tumor response, and 
survival in these patients to see if timing of TMZ therapy alters any of these clinical outcomes. 
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We will also monitor daily rest-activity rhythms to correlate the behavioral circadian rhythms of 
these patients to clinical outcomes. This prospective clinical trial will gather information to lay 
the groundwork for larger trials that could be created in the future.  
The outcomes of these studies could be applied to the use of other DNA damaging agents 
in the future, including ionizing radiation. Rahn and colleagues published a study reporting 
greater survival of patients with brain metastases of non,small cell lung cancer following gamma 
knife radiosurgery in the morning compared to afternoon [150]. If the principles underlying the 
circadian regulation of DNA damage response can be applied to all treatments that induce DNA 
double strand breaks, then this study provides the basis for applications to a variety of cancer 
types and treatment types. To determine how generalizable the findings of this study might be, it 
will be important to test for circadian regulation of DNA damage response in a variety of cell 
types. It will also be important to test a variety of DNA-damaging agents. The pharmacokinetics 
of other chemotherapies may guide the optimal timing of treatment, but the immediate formation 
of double strand breaks following ionizing radiation makes radiation therapy a logical next step 
in testing the generalizability of chronomodulation of therapeutic DNA-damaging agents in the 
treatment of GBM, and other cancers. 
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Conclusions 
 The mechanism by which daily oscillations occur in TMZ sensitivity to glioblastoma 
remains unclear; however, we were able to demonstrate for the first time a Bmal1-dependent 
rhythm in sensitivity to DNA damaging chemotherapy in GBM in vitro. Our study extends the 
chronotherapy literature to a new class of chemotherapy, DNA alkylators. The consistency of our 
findings with the findings of other studies evaluating the circadian regulation of tumor response 
to DNA damage demonstrates a common outcome among different cancer cell types and 
different DNA-damaging agents.  This suggests that the mechanism of cellular response to DNA 
damage may be the common pathway regulated in response to a variety of chemotherapies. 
Future studies are necessary to identify the specific mechanism of circadian regulation of DNA 
damage response. Identification of such a mechanism would allow us to extend the application 
chronotherapy to even more chemotherapies and cancer types.  
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